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Summary
In 2005, two tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines were licensed and recom-
mended for use in adults and adolescents in the United States: ADACEL® (sanofi pasteur, Swiftwater, Pennsylvania), which is
licensed for use in persons aged 11–64 years, and BOOSTRIX® (GlaxoSmithKline Biologicals, Rixensart, Belgium), which is
licensed for use in persons aged 10–18 years. Both Tdap vaccines are licensed for single-dose use to add protection against pertussis
and to replace the next dose of tetanus and diphtheria toxoids vaccine (Td). Available evidence does not address the safety of Tdap
for pregnant women, their fetuses, or pregnancy outcomes sufficiently. Available data also do not indicate whether Tdap-induced
transplacental maternal antibodies provide early protection against pertussis to infants or interfere with an infant’s immune
responses to routinely administered pediatric vaccines. Until additional information is available, CDC’s Advisory Committee on
Immunization Practices recommends that pregnant women who were not vaccinated previously with Tdap: 1) receive Tdap in
the immediate postpartum period before discharge from hospital or birthing center, 2) may receive Tdap at an interval as short as
2 years since the most recent Td vaccine, 3) receive Td during pregnancy for tetanus and diphtheria protection when indicated, or
4) defer the Td vaccine indicated during pregnancy to substitute Tdap vaccine in the immediate postpartum period if the woman
is likely to have sufficient protection against tetanus and diphtheria. Although pregnancy is not a contraindication for receiving
Tdap vaccine, health-care providers should weigh the theoretical risks and benefits before choosing to administer Tdap vaccine to
a pregnant woman. This report 1) describes the clinical features of pertussis, tetanus, and diphtheria among pregnant and
postpartum women and their infants, 2) reviews available evidence of pertussis vaccination during pregnancy as a strategy to
prevent infant pertussis, 3) summarizes Tdap vaccination policy in the United States, and 4) presents recommendations for use of
Td and Tdap vaccines among pregnant and postpartum women.
Introduction
Pertussis is an acute and prolonged infectious cough illness
caused by Bordetella pertussis, a fastidious gram-negative coc-
cobacillus. Pertussis results in substantial morbidity among
adults and adolescents whose immunity to past childhood
vaccination or B. pertussis infection might have waned and
who have not received booster immunization for pertussis with
adult tetanus, reduced diphtheria, and acellular pertussis
(Tdap) vaccine (1,2). In 2004, women aged 15–39 years
accounted for 97% of all live births in the United States (3).
During 2000–2006, a total of 103,940 cases of pertussis were
reported to CDC’s National Notifiable Diseases Surveillance
System (NNDSS); 27,759 (27%) of these cases occurred
among persons aged 15–39 years (CDC, unpublished data,
2007). Parents with pertussis, including new mothers, are the
identified source of B. pertussis infection in >25% of pertussis
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* The recommended childhood schedule of pediatric DTaP is a dose at ages
6–8 weeks, at 4 months, and at 6 months and a booster dose at age 15–18
months and at age 4–6 years (23).
cases in early infancy, when rates for complications and fatali-
ties are highest (4–8). Infants aged <12 months accounted for
145 (93%) of 156 pertussis-related deaths reported to CDC
for 2000–2006 (CDC, unpublished data, 2007). Decennial
booster vaccination with adult tetanus toxoid and reduced
diphtheria toxoid (Td) vaccine has been largely responsible
for reducing the average annual number of tetanus and respi-
ratory diphtheria cases reported during 2000–2006 to 31 and
less than one, respectively. In contrast, the average annual
number of pertussis cases was 14,849 during the same period
(9–15; CDC, unpublished data, 2007).
In 2005, two Tdap vaccines were licensed in the United
States: ADACEL® (sanofi pasteur, Swiftwater, Pennsylvania)
for use in persons aged 11–64 years (16) and BOOSTRIX®
(GlaxoSmithKline Biologicals, Rixensart, Belgium) for per-
sons aged 10–18 years (17) (Table 1). Both vaccines are
licensed for single-dose administration. Acellular pertussis vac-
cines formulated with tetanus and diphtheria toxoids also are
available for adults and adolescents in other countries, includ-
ing an increasing number of European countries (e.g., France,
Austria, and Germany), Canada, and Australia (18–20). No
vaccine containing acellular pertussis antigens without teta-
nus and diphtheria toxoids is available in the United States.
Vaccinating adults and adolescents using Tdap reduces the
burden of pertussis among vaccine recipients and might pre-
vent transmission of B. pertussis to infants (1,2). Statements
and recommendations by CDC’s Advisory Committee for
Immunization Practices (ACIP) regarding use of Tdap by
adults, including health-care personnel, and adolescents
(Table 2) provide background information on pertussis and
extensive discussion regarding the safety and immunogenic-
ity of Tdap in prelicensure trials. These recommendations
encourage adult and adolescent women of childbearing age to
receive Tdap at a routine health assessment before conception
to prevent the morbidity of pertussis that could occur during
pregnancy and encourage use of Tdap among adults and ado-
lescents who anticipate contact with an infant aged <12 months
both for personal protection and to reduce the risk for trans-
mitting B. pertussis to the infants (1,2).
In 2006, ACIP recommended routine administration of
Tdap for postpartum women who were not vaccinated previ-
ously with Tdap to provide personal protection and reduce
the risk for transmitting pertussis to their infants (1,2) . After
careful consideration, in June 2006, ACIP voted to reaffirm
its recommendation for use of Td in pregnant women who
have urgent indication for tetanus toxoid or diphtheria tox-
oid vaccination to prevent maternal or neonatal tetanus, or to
prevent diphtheria. Pregnant women not vaccinated previously
with Tdap will receive a measure of protection against pertus-
sis by ensuring that children in the household are up-to-date
with recommended doses of pediatric diphtheria and tetanus
toxoids and acellular pertussis vaccine (DTaP)* (21–23) and
that adult and adolescent household contacts have received a
dose of Tdap (Table 2) (1,2). Health-care providers can moni-
tor pregnant women who have not received a dose of Tdap
for exposures to pertussis or to respiratory illness consistent
with pertussis, and they can administer antimicrobials for
postexposure prophylaxis or treatment of pertussis, if needed,
to reduce the risk for transmitting pertussis to their infants.
This report provides the background and rationale for rou-
tine administration of Tdap in postpartum women who were
not vaccinated previously with Tdap and for maintaining the
previous recommendation for use of Td in pregnant women
if indicated. The safety and efficacy of using Tdap in preg-
nant women has not been demonstrated, and Tdap is not rec-
ommended for use in pregnant women in any country. No
evidence exists of excess morbidity or any fatality among preg-
nant women ascribed to pertussis. No evidence exists demon-
strating whether
• Tdap in pregnant women harms the fetus or increases
risk for adverse pregnancy outcomes,
• transplacental antibody induced by Tdap administered
during pregnancy will protect infants against pertussis,
or
• Tdap-induced transplacental maternal antibody will have
a negative impact on an infant’s protective immune
response to later-administered routine pediatric DTaP or
to conjugate vaccines containing tetanus toxoid or diph-
theria toxoid.
This report discusses certain situations in which health-care
providers might choose to administer Tdap to a pregnant
woman. Health-care providers should weigh the theoretical
risks and benefits before choosing to administer Tdap vaccine
to a pregnant woman.
Methods
During June 2006, ACIP evaluated the limited evidence
available concerning safety, immunogenicity, and pregnancy
outcomes after administration of Tdap; evidence from his-
toric use of pertussis, tetanus, and diphtheria vaccines in preg-
nant women; and the potential effects of transplacental
maternal antibody on the infant’s immune response to active
immunization with pediatric diphtheria and tetanus toxoids
and whole-cell pertussis (DTP) or DTaP vaccines, or to con-
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jugate vaccines containing tetanus toxoid or diphtheria tox-
oid. The evaluation included a synthesis of information from
scientific literature published in English, unpublished sources
of information, consultations, analyses, and extensive discus-
sion by an ACIP working group† during 2005–2006. The
working group comprised persons with expertise in pertussis,
tetanus, and diphtheria; obstetrics and gynecology; pediat-
rics, family practice, internal medicine, immunology, public
health, and vaccine regulation; and liaison members from part-
ner organizations.
The workgroup considered multiple diverse views on the
adequacy of evidence needed to form a recommendation for
use of Tdap in pregnant and postpartum women. A minority
view held that available data from nonpregnant women and
men, and experience with the use of Td in pregnant women
to prevent neonatal and maternal tetanus, were sufficient to
support a recommendation for the safe use of Tdap in preg-
nant women for individual protection from pertussis. The
majority view, while acknowledging the desirability of pre-
venting pertussis in pregnant women and the substantial body
of information demonstrating the usefulness of Td to prevent
maternal and neonatal tetanus, held that the evidence was
insufficient at this time to support a recommendation for
routine administration of Tdap in pregnant women. The spe-
cific issues for pertussis differ from those for tetanus and diph-
theria. Important among these is the limited understanding
of immunity and correlates of protection for pertussis. In
addition, data supporting the safety of vaccinating pregnant
women with Tdap to prevent pertussis are scarce for women,
their fetuses, and pregnancy outcomes. Whether transplacen-
tal maternal antibody exerts an inhibitory or other effect on
the infant-protective immune response to active immuniza-
tion with pediatric DTaP or conjugate vaccines containing
tetanus toxoid or diphtheria toxoid has not been studied. Pro-
tection against infant pertussis through Tdap-induced trans-
placental maternal antibody has not been demonstrated. Until
additional information is available, the majority view of the
working group held that Tdap administered to women in the
immediate postpartum period, in addition to ensuring per-
tussis vaccination of close contacts, would likely provide a
measure of protection for mother and infant.
Pertussis
B. pertussis, the organism that causes pertussis, elaborates
multiple toxins, including tracheal cytotoxin, which damages
the respiratory epithelial tissue in vitro (24), and pertussis toxin,
which has systemic effects (e.g., promoting lymphocytosis)
(25). Illnesses caused by other species of Bordetella are not
considered preventable by available pertussis vaccines (26,27).
Clinical Features
B. pertussis infections and reinfections among adults and ado-
lescents can be asymptomatic or range from a mild cough
illness to the severe, prolonged cough illness of classic pertus-
sis (28). The clinical presentation of pertussis can be similar
to that for respiratory illness caused by B. parapertussis,
B. bronchiseptica, B. holmseii, Mycoplasma pneumoniae,
Chlamydia (Chlamydophila) pneumoniae, and multiple viral
agents (e.g., adenovirus, parainfluenza virus, human meta-
pneumovirus, influenza virus, rhinovirus, and coronavirus).
The incubation period for pertussis typically is 7–10 days
(range: 5–21 days) (29,30).
Classic pertussis is characterized by three phases: catarrhal,
paroxysmal, and convalescent (28,29). The catarrhal phase
lasts 1–2 weeks and consists of a watery nasal discharge and
frequent cough, frequent sneezing, and injection of the con-
junctiva, often with lacrimation. The cough typically suggests
tracheal irritation (e.g., a tickle in the throat) and is short,
sharp, hacking, and isolated (as distinguished from paroxys-
mal). The cough is equally persistent during day and night
and rarely croupy or hoarse. Fever is uncommon during any
phase unless the illness is complicated by secondary infection
or coinfection (28). The paroxysmal phase lasts 2–6 weeks.
The patient has intermittent periods of intense coughing (par-
oxysms) alternating with periods of appearing relatively well
with a normal respiratory rate. The paroxysms are character-
ized by spasms of coughing, choking, posttussive vomiting,
and inspiratory whoop (29,31). Adults experience greater
severity of illness than adolescents, including cough-related
incontinence in 28% of cases in women; in up to 5% of cases,
adults and adolescents experience one or more rib fracture,
syncope, or pneumonia, or they require hospitalizations
(1,2,31,32). Approximately one third of adults and adoles-
cents lose weight during the illness (31,33). Anecdotal reports
of pneumothorax, seizures, stroke, and other complications
have been summarized previously (1,34). The convalescent
phase of pertussis typically lasts 2–6 weeks (35). Symptoms
can persist for >6 months (1,2). Factors that can lessen the
severity of B. pertussis infection include residual immunity from
previous infection or vaccination and use of macrolide anti-
microbials in the catarrhal (early) phase of the illness (36).
Adults and adolescents with pertussis make repeated medi-
cal visits and miss work and school. During 1998–2000 in
Massachusetts, among 936 adults and 1,679 adolescents
reported with confirmed pertussis, the median number of† A list of members appears on inside back cover of this report.
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TABLE 1. Disease-specific composition of vaccines containing tetanus toxoid, with and without diphtheria toxoid and acellular
pertussis antigens, by age and vaccine type — United States, 2008*
Diphtheria Tetanus
   Pertussis antigens (µg)† toxoid† (DT) toxoid† (TT)
Age and vaccine type Trade name Manufacturer PT¶ FHA** PRN†† FIM§§ (Lf§) (Lf)
For age <7 yrs
DTaP¶¶ INFANRIX® GlaxoSmithKline 25 25 8 25 10
Biologicals (GSK)
DTaP-IPV-Hep B§§§ PEDIARIX™ GSK 25 25 8 25 10
 DTaP DAPTACEL™ sanofi pasteur 10 5 3 5¶¶¶ 15 5
DTaP, DTaP-Hib Tripedia,® sanofi pasteur 23.4 23.4 6.7 5
TriHIBit® sanofi pasteur
(Tripedia® + ActHIB®)††††
DT§§§§ No trade name sanofi pasteur 6.7 5
For age >7 yrs
Tdap¶¶¶¶ BOOSTRIX®***** GSK 8 8 2.5 2.5 5
Tdap ADACEL®††††† sanofi pasteur 2.5 5 3 2 5
Td§§§§§ No trade name Massachusetts Public  2 2
Health Biologic Laboratory
Td No trade name MassBioLogics 2 2
Td DECAVAC™ sanofi pasteur 2 5
TT¶¶¶¶¶ (adsorbed) No trade name sanofi pasteur 5
* Limited to vaccines licensed and marketed in the United States. Consult package inserts for prescribing information, age indication, and additional
product information: package inserts are routinely updated. Additional information is available at http://www.fda.gov/cber/index.html.
† Per recommended dose of 0.5 mL.
§ Limit of flocculation




¶¶ Pediatric diphtheria and tetanus toxoids and acellular pertussis vaccine.
*** Residual 2-phenoxyethanol, not used as a preservative.
††† The tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber; the vial stopper is latex-free.
§§§ Tetanus, diphtheria, and pertussis components are the same as those in INFANRIX®; also contains hepatitis B surface antigen, and inactivated
polioviruses Type 1 (Mahoney), Type 2 (MEF-1), and Type 3 (Saukett).
¶¶¶ Fimbriae types 2 and 3.
**** The stopper to the vial contains dry natural rubber that might cause allergic reactions in latex-sensitive person
†††† Tripedia® reconstituted with ActHIB.® The tetanus, diphtheria, and pertussis components are the same as those in Tripedia®; ActHIB® contains
Haemophilus influenzae type b polysaccharide–tetanus toxoid conjugate.
§§§§ Pediatric diphtheria and tetanus toxoids.
¶¶¶¶ Tetanus toxoid and reduced diphtheria toxoid and accellular pertussis vaccine.
***** Indicated as a single dose for persons aged 10–18 years.
††††† Indicated as a single dose for persons aged 11–64 years.
§§§§§ Tetanus and reduced diphtheria toxoids.
¶¶¶¶¶ Tetanus toxoid.
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TABLE 1. (Continued ) Disease-specific composition of vaccines containing tetanus toxoid, with and without diphtheria toxoid
and acellular pertussis antigens, by age and vaccine type — United States, 2008*
Thimerosal                          Preservative
Adjuvant: aluminum (Al) (methyl mercury Other
How supplied salt (mg Al/dose) per 0.5 mL dose) (content per dose) Latex Other inactive components†
Single dose Hydroxide (0.625 mg Al) 0 No*** (2.5 mg) Yes††† <100 µg residual formaldehyde
<100 µg Tween 80
Single dose Hydroxide (DTaP), 0 None Yes††† <100 µg residual formaldehyde
Phosphate (Hep B) <100 µg Tween 80
(<0.85 mg Al total) <0.05 ng neomycin sulfate
<0.01ng polymyxin B
<5% yeast protein
Single dose Phosphate (0.33 mg Al) 0 No*** (3.3 mg) Yes**** <5 µg residual formaldehyde
<50 ng glutaraldehyde
Single dose Sulfate (<0.17 mg Al) <0.3 µg (trace) None Yes**** <100 µg residual formaldehyde
Tween 80
Gelatin
Single dose Sulfate (<0.17 mg Al) <0.3 µg (trace) None Yes**** <100 µg residual formaldehyde
Single dose Hydroxide (<0.39 mg Al) 0 None Yes††† <100 µg residual formaldehyde
<100 µg Tween 80
Single dose Phosphate (0.33 mg Al) 0 No*** (3.3 mg) No <5 µg residual formaldehyde
<50 ng glutaraldehyde
Multidose Phosphate (0.45 mg Al) 8.3 µg None Yes**** <100 µg residual formaldehyde
Single dose Phosphate (0.45 mg Al) <0.3 µg (trace) None No <100 µg residual formaldehyde
Single dose Sulfate (0.28 mg Al) <0.3 µg (trace) None No <100 µg residual formaldehyde
Single dose Sulfate (0.25 mg Al) <0.3 µg (trace) None No <100 µg residual formaldehyde
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TABLE 2. Summary of recommendations of the Advisory Committee on Immunization Practices (ACIP) for vaccination to
prevent pertussis, tetanus, and diphtheria among adults and adolescents,* with recommended intervals for vaccination from
the most recent tetanus and diphtheria toxoids-containing vaccine† — United States, 2006–2008
May 2008
March 2006 December 2006 Women of childbearing age, including
Setting Adolescents (aged 11–18 yrs) Adults (aged 19–64 yrs) pregnant and postpartum women
Tdap to replace the next decennial Td¶; Tdap is
encouraged during preconception wellness visits
Tdap postpartum before leaving hospital or birthing
center; interval as short as 2 yrs¶**††
• Td recommended during pregnancy,†† or
• Tdap-postpartum before leaving hospital or birthing
center instead of Td during pregnancy, if sufficient
tetanus and diphtheria protection is likely until delivery
Tdap, ideally administered at least 2 wks before contact
with the infant; interval as short as 2 yrs suggested¶
Tdap-postpartum before leaving hospital or birthing
center; interval as short as 2 yrs¶**††; pregnant women
should be advised of symptoms of pertussis and the
benefits of treatment and early prophylaxis for
household contacts exposed to pertussis
Td for urgent protection during pregnancy††; Tdap
postpartum before leaving hospital or birthing center
Td when indicated for pregnant women††§§
1 dose Td during pregnancy followed by dose 2 Td







Nonpregnant adults and adolescents
who anticipate having, or will have
contact with an infant aged <12 mos
Increased risk for pertussis or its
complications, e.g., health-care
personnel with direct patient contact
and persons in settings with a
pertussis outbreak
Increased risk for diphtheria
Tetanus wound management
No tetanus and diphtheria toxoids
vaccination, or vaccination history
incomplete or unknown
Tdap at age 11–12 yrs; Tdap
catch-up ages 11-18 yrs§




Tdap at age 11–12 yrs;
Tdap catch-up ages 11–18 yrs§
Tdap ages 11–18 yrs§
Tdap, when indicated§
Tdap instead of Td when
indicated§§
1 dose Tdap, followed by
Td >4 wks later and dose 2 Td
6–12 mos later
Tdap to replace the next decennial
Td¶; ideally, women will receive
Tdap before becoming pregnant
Tdap postpartum before leaving
hospital or birthing center; interval
as short as 2 yrs¶
Td recommended during pregnancy
Tdap ideally administered at least
2 wks before contact with the infant;
interval as short as 2 yrs
suggested¶
Tdap; interval as short as 2 yrs¶
Tdap to replace the next Td when
indicated*
Tdap instead of Td when
indicated§§
1 dose Tdap, followed by Td
>4 wks later and dose 2 Td
6–12 mos later
Sources: CDC. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. Recommenda-
tions of the Advisory Committee on Immunization Practices (ACIP). MMWR 2006;55(No. RR-3). CDC. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus
toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap). Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR 2006;55 (No. RR-17).
* ACIP recommends routine vaccination with tetanus and diphtheria toxoids every 10 years to boost tetanus and diphtheria protection. In 2006, ACIP recommended that adults and
adolescents who have not been vaccinated previously with tetanus and reduced diphtheria toxoids and acellular pertussis (Tdap), including persons with a history of pertussis,
receive a dose of Tdap to boost pertussis protection in addition to tetanus and diphtheria protection. Tdap is licensed for single-dose administration. In persons who have received
Tdap, tetanus and reduced diphtheria toxoids (Td) vaccine should be administered when subsequent decennial booster vaccination is indicated for tetanus or diphtheria
protection.
† For adults and adolescents, tetanus and diphtheria toxoids–containing vaccines include tetanus toxoid (TT), Tdap, and Td; for infants and children, tetanus toxoid and diphtheria
toxoids–containing vaccines include pediatric diphtheria and tetanus toxoids and whole-cell pertussis (DTP), pediatric diphtheria and tetanus toxoids and acellular pertussis (DTaP),
pediatric diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus and hepatitis B (DTaP-IPV-Hep B), and pediatric diphtheria and tetanus toxoids (DT).
§ During 2000–2006, U.S. adolescents aged 10–19 years had the highest incidence of reported pertussis outside of infancy (CDC, unpublished data, 2008). For this reason, a
catch-up dose of Tdap is recommended for adolescents aged 11–18 years to add protection against pertussis if they have received Td but not Tdap. For catch-up Tdap, an
interval of at least 5 years from the most recent tetanus and/or diphtheria toxoids–containing vaccine is encouraged to reduce the risk for local and systemic reactions that could
result when concentration of tetanus and/or diphtheria antitoxin is high. An interval less than 5 years after Td may be used, particularly when the benefit of providing pertussis
protection is likely to be increased. Adolescents who have received a childhood series of pediatric DTP or DTaP and Td or Tdap are protected against tetanus and diphtheria.
¶ A shorter interval may be used.
** Limited evidence informs the risk of local and systemic reactions after Tdap at intervals of <2 years. Higher rates of local and systemic reactions and more severe reactions can
occur with high preexisting serum titers of tetanus or diphtheria antitoxin. Providers may choose to administer Tdap in postpartum women who received a tetanus toxoid– and/or
diphtheria toxoid–containing vaccine (e.g., Td or TT) less than 2 years previously if the women have no history of serious adverse reaction after the most recent dose of tetanus
and/or diphtheria toxoid–containing vaccine.
†† In special situations, a dose of Tdap might be warranted during pregnancy. Health-care providers who choose to administer Tdap to pregnant women should discuss with the
women the lack of evidence of safety and effectiveness for the mother, fetus, pregnancy outcome, and effectiveness of transplacental maternal antibodies to provide early
pertussis protection to the infant. These women should be informed that no study has examined the effectiveness of transplacental pertussis antibodies induced by Tdap on the
adequacy of the infant immune response to pediatric DTaP and conjugate vaccines containing tetanus toxoid or diphtheria toxoid. Because adverse outcomes of pregnancy are
most common in the first trimester, vaccinating these pregnant women with Tdap during the second or third trimester is preferred to minimize the perception of an association of
Tdap with an adverse outcome, unless vaccine is needed urgently.
§§ A Td booster might be recommended for wound management if >5 years have elapsed since the previous Td. Persons who have completed the 3-dose primary tetanus
vaccination series and have received a tetanus toxoid–containing vaccine within the preceding 5 years are protected against tetanus and do not require a tetanus toxoid–
containing vaccine as part of wound management.
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medical visits was two (range: 0–15) (31). Among 203 adults
and 314 adolescents with confirmed pertussis who were
interviewed during 2001–2003, 158 (78%) adults were
employed. Of these employed adults, 123 (78%) missed work
(mean: 9.8 days; range: 0.1–180 days); 261 of the 314 (83%)
adolescents missed school (mean: 5.5 days; range: 0.4–32
days). Among primary caregivers for adolescents, 136 of 314
(43%) missed work (mean: 2.4 days; range: 0.1–25 days); a
second caregiver in 53 families also missed work (mean: 1.8
days; range: 0.1–11 days) (31).
Pertussis is transmitted from person to person via large res-
piratory droplets generated by coughing or sneezing; early
reports suggested that B. pertussis can be recovered from dried
mucus for up to 3 days (28,30). Pertussis is highly infectious,
with attack rates among exposed, nonimmune household con-
tacts as high as 80%–90% (29,37,38). The most infectious
periods are the catarrhal and early paroxysmal phases (28).
Untreated patients, particularly infants, remain infectious for
6 weeks or longer (29). Among older children and adults with
previous vaccination or infection, the infectious period typi-
cally is <21 days (29).
In a Canadian study conducted in 1999, a source was iden-
tified in 60%–70% of adults and adolescents with pertussis.
Among adults aged 18–39 years, the source was a person in
the household in 25%–44% of cases or at work or school in
17%–25% of cases. Among adolescents aged 12–17 years, the
source was a person in the household in 9% of cases and a
friend or person at school or work in 51% of cases (39).
Pertussis During Pregnancy
Case reports suggest that the morbidity of pertussis is not
increased among pregnant women compared with nonpreg-
nant women. In a general medical practice during 1979–1980,
four pregnant women had onset of cough during the 12th,
14th, 14th, and 36th week of gestation and cough that lasted
36, 6, 8, and 6 weeks, respectively; two women had vomiting
after coughing and worsening cough paroxysms at night; and
one woman developed hemoptysis and subconjunctival hem-
orrhage after repeated and forceful coughing paroxysms (40).
A 1993 case report described a pregnant woman who was
hospitalized 6 days before delivery for severe paroxysms and
posttussive emesis (41). In a series of 32 women who had
pertussis during pregnancy or at term, the illness was charac-
terized as “a very tiresome disease”; no obstetric complication
was reported, and no infant was premature (42). No pertus-
sis-related deaths have been reported in pregnant women. The
source of pertussis in infected pregnant women has not been
examined systematically.
Reports of fetal morbidity among pregnant women with
pertussis are rare, and no causal relationship with abnormal
fetal development, fetal morbidity, or adverse outcome of preg-
nancy has been confirmed. One fetus of a mother who had
severe paroxysmal coughing early in pregnancy had an extra-
dural hematoma that was identified by ultrasonography and
magnetic resonance at 31 weeks’ gestation; studies had been
normal at 12 and 22 weeks’ gestation (43). Another fetus of a
mother who had pertussis during the first trimester had pre-
natal diagnosis of laryngotracheal obstruction (44).
Infantile Pertussis
Infants aged <12 months typically have the most severe per-
tussis, often requiring hospitalization for respiratory or other
complications (Table 3) (8,45–49). The risk for pertussis death
or severe pertussis is highest among infants in the first 6 months
of life and remains elevated until infants have received
1–2 doses of pediatric DTaP (8,50,51). During 2000–2006,
the average annual incidence of pertussis among infants
aged <6 months was 111 cases per 100,000 population; for
infants aged 6–11 months, incidence was 19 cases per 100,000
population (CDC, unpublished data, 2007).
Complications and deaths from infant pertussis have been
characterized by necrotizing bronchiolitis (52) and high rates
of primary or secondary pneumonia and/or coinfection with
bacterial and viral pathogens (8,28,47,53). Since 1993, pul-
monary hypertension has been increasingly recognized among
fatal infant cases (47,52,54–58). The majority of all infant
deaths have occurred among unvaccinated infants (47,53,58;
CDC, unpublished data, 2007). Hispanic infants and infants
born at estimated gestational age <37 weeks or with low birth
weight have comprised a larger proportion of pertussis deaths
than would have been expected on the basis of population
TABLE 3. Number* and percentage of hospitalizations and
complications among infants aged <12 months with reported








Source: CDC’s National Notifiable Diseases Surveillance System and
Supplemental Pertussis Surveillance System, 2000–2006.
* N = 18,564.
†Percentages are based on total number with information. For 20% of
cases, no information was available on hospitalization or apnea; for 21%,
no information was available on seizure; and for 33%, no information
was available on pneumonia. Because multiple complications might have
been reported, totals do not add to 100%.
§Confirmed radiographically.
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estimates (47,53,58). Compared with the prevaccine era, dur-
ing 2000–2006, the proportion of reported pertussis deaths
among infants aged <3 months increased from 37% to 83%
(Figure 1) (38,47; CDC, unpublished data, 2007).
Since the 1970s, parents, especially mothers, have been iden-
tified as the most important source of infant pertussis; how-
ever, a source has been identified in only 30%–60% of cases
investigated (5–7,34,38,42,48,59–68). One or more house-
hold contact with pertussis is the source of pertussis in
approximately 75% of cases among infants aged <6 months
for whom the source is identified. A parent is implicated in
approximately 25% of cases in infants, including the mother
in 16%–19% of cases. A sibling is implicated as the source of
transmission in <10% of cases (5,7,34).
Mathematical modeling evaluating different vaccine strate-
gies for the United States has suggested that pertussis vaccina-
tion of 90% of household contacts (children, adolescents, and
adults) of newborns, in addition to pertussis vaccination of
75% of adolescents generally in the population, might pre-
vent approximately 75% of pertussis cases among infants aged
0–23 months (69). Another model estimated vaccination of
both parents of an infant before discharge from the hospital could
prevent 38% of infant cases and deaths (70). However, the effi-
cacy of these strategies in practice has not been evaluated.
Disease Burden
Although pertussis is a nationally notifiable disease in the
United States (71), data on the pregnancy status of women
with pertussis have not been collected. However, the burden
of pertussis among pregnant women is likely to be similar to
the burden among other adults in the population. Pertussis
reports typically demonstrate increases in activity every 3–4
years (72); aside from these cycles of activity, the number of
reported cases of pertussis in the United States has increased
gradually since 1976. During 2004–2005, more than 25,000
cases were reported per year (Figure 2). During 2006, a total
of 15,632 pertussis cases were reported, including 2,029 (13%)
cases among infants, 5,045 (32%) cases among children aged
1–14 years, 5,148 (33%) cases among persons aged 15–39
years, and 3,331 (21%) cases among adults aged >40 years.
A total of 40 pertussis-related deaths were reported in 2005
and 16 in 2006; 39 (98%) of these deaths occurred among
infants in 2005 and 14 (88%) in 2006 (CDC unpublished
data, 2007). Prospective and serologic studies suggest that
pertussis infection and reinfection are underrecognized among
adults and adolescents (29,73–75). The pertussis burden is
believed to be substantially more than the number of reported
cases; approximately 600,000 cases are estimated to occur
annually just among adults (1,34,76).
Transmission in Obstetric and
Neonatal Health-Care Settings
Health-care personnel can transmit B. pertussis in health-care
settings if pertussis has not been considered by hospital staff
(1,77,78). Outbreaks have been documented in prenatal and
postnatal clinics (79,80), maternity wards (51,62,81–83),
neonatal nurseries, and neonatal intensive-care services
(62,81,84–90). Ongoing transmission is facilitated by delay
in isolation and treatment of patients and in prophylaxis of
contacts and by inconsistent use of face or nose and mouth
protection (1,85,87,91). Unprotected exposures to pertussis
in health-care settings can result in labor-intensive, disrup-
tive, and costly investigations and control measures, particu-
larly when the number of contacts is substantial (80,92).
Pertussis transmitted to health-care personnel or patients can
result in substantial morbidity (and on rare occasions in fatal
disease) among hospitalized infants (79,80,85–88,93,94).
Health-care personnel who have not been vaccinated with
Tdap (Table 2) can be an important source of pertussis and
pertussis outbreaks in obstetric and neonatal settings. A wide
range of health-care disciplines have been implicated, includ-
ing physicians, resident physicians, and students (80,82,
85,95); nurses and nurse midwives (51,81,85,87,96–98); and
aides, medical assistants, and educators (1,51,78,79,81,82,
85,87). Pregnant and postpartum women with unrecognized
pertussis and visitors to prenatal, obstetric, and neonatal units,
including fathers and other close relatives, pose a substantial
FIGURE 1. Proportion of reported infant pertussis deaths, by
age — United States, 1938–1940,* 1990–1999,† and 2000–2006§
* Source: Sako W, Treuting WL, Witt DB, Nichamin SJ. Early immunization
against pertussis with alum precipitated vaccine. JAMA 1945;127:379–
84. N = 7,123 reported infant pertussis deaths.
†Source: Vitek CR, Pascual FB, Baughman AL, Murphy TV. Increase in
deaths from pertussis among young infants in the United States in the
1990s. Pediatr Infect Dis J 2003; 22:628–34. N = 93 reported infant
pertussis deaths.
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risk for transmission to infants, pregnant women, and health-
care personnel and have been associated with outbreaks in
these settings (6,41,62,80,81,84–86,93,98). Early recognition
and treatment of pertussis in pregnant and postpartum women
and prophylaxis of household contacts who visit health-care
settings is critical to prevent continuing transmission. Antimi-
crobial treatment for women who have pertussis near term or
at delivery and prophylaxis for their newborns and household
contacts are effective in preventing further transmission (42,99).
Diagnosis
The diagnosis of pertussis is complicated by the limitations
of currently available diagnostic tests. The only pertussis
diagnostic tests that are accepted to confirm a case for pur-
poses of national reporting are culture and polymerase chain
reaction (PCR) (when the clinical case definition also is met)
(100; Box 1). Multiple factors affect the sensitivity, specific-
ity, and interpretation of diagnostic tests for pertussis
(101,102).
Culture
Culture to isolate B. pertussis is essential for identifying the
organism early in the course of disease (103) and for antimi-
crobial susceptibility testing, if indicated. Isolation of
B. pertussis by culture is 100% specific; for opti-
mal yield, culture requires specimens that con-
tain nasopharyngeal cells obtained by aspirate or
nasopharyngeal swab and special medium for
growth. The sensitivity of culture early in per-
tussis varies (range: 30%–60%) (103–105).
Outside of infancy, the yield of B. pertussis
declines to 1%–3% in specimens taken in the third
week of cough illness or later, after starting anti-
microbial treatment, or in a patient who was vac-
cinated previously (106,107). B. pertussis can be
isolated in culture as early as 72 hours after plat-
ing but requires 1–2 weeks before a result can
definitively be called negative (108).
Polymerase Chain Reaction
DNA amplification (e.g., PCR) to detect
B. pertussis has increased sensitivity and more
rapid turnaround time (109–111). When symp-
toms of classic pertussis are present (e.g., >2 weeks
of paroxysmal cough), PCR can be two to three
times more likely than culture to detect
B. pertussis in a known positive sample
(101,103,112,113). As with culture, the PCR
result is affected by the technique used to collect
the specimen; a poorly taken nasopharyngeal swab is more
likely to be negative by both culture and PCR. PCR is less
affected than culture by antimicrobial therapy because the
organism does not need to be viable for the test to be positive.
Adults and adolescents who have specimens taken later in the
course of illness, who have started antibiotic treatment, or
who were vaccinated previously tend to have PCR-positive,
culture-negative test results (103,114).
Although PCR testing for pertussis has been available for
nearly 20 years (115), no U.S. Food and Drug Administra-
tion (FDA)–licensed PCR test kit is available. The analytical
sensitivity, accuracy, and quality control of PCR-based
B. pertussis tests vary widely among laboratories. PCR assays
used by the majority of laboratories amplify a single gene
sequence, typically within the insertion sequence IS481. Both
false-positive and false-negative results have been reported with
these assays; reported outbreaks of respiratory illness mistak-
enly attributed to pertussis have resulted in unnecessary
investigation and treatment, and unnecessary chemoprophy-
laxis of contacts (112,116–119). Using more than one
genetic target and consensus interpretation criteria for PCR
diagnosis of pertussis (120,121) has been suggested as a way
to provide increased assurance of specificity (122) and to
allow discrimination between Bordetella species.
FIGURE 2. Number of reported pertussis cases, by year — United States,
1922–2006*
* Sources: For 1950–2006, CDC, National Notifiable Diseases Surveillance System;
for 1922–1949, passive reports to the U.S. Public Health Service.
†Universal pediatric diphtheria and tetanus toxoids and whole-cell pertussis (DTP)
vaccine was recommended in the United States in the late 1940s.
§Adolescent (ages 11–18 years) and adult (ages 19–64 years) single-dose tetanus
toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine was available
in the United States in 2005 and was recommended in 2006 for use in adults aged
19–64 years and adolescents aged 11–18 years.
¶ Universal pediatric diphtheria and tetanus toxoids and acellular pertussis (DTaP)
vaccine was recommended in the United States for doses 4 and 5 in1991 and for
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Other Diagnostic Tests
Direct fluorescent antibody (DFA) tests provide rapid
results (within hours), but sensitivity (10%–50%) is less than
with culture (123). With use of monoclonal reagents, the speci-
ficity of DFA should be >90%. However, interpretation of
the test is subjective, and, when interpreted by an inexperi-
enced microbiologist, the specificity can be lower (110).
Diagnosis of pertussis by serology requires a substantial change
in titer for pertussis antigens (typically fourfold) from acute
(<2 weeks after cough onset) to convalescent sera (>4 weeks
after the acute sample). The results typically become available
too late in the course of the illness to be useful clinically. Single-
sample serologic tests for antipertussis toxin (anti-PT) IgG
have been developed for research purposes; sera must be col-
lected at least 2 weeks after the onset of symptoms (124).
Pertussis serology assays using commercial reagents are avail-
able, but these assays are not validated clinically and do not
differentiate between recent and remote infection and vacci-
nation (125,126). No serologic assay is licensed by FDA for
routine diagnostic use in the United States.
Postexposure Prophylaxis
and Treatment
A macrolide (erythromycin, azithromycin, or clarithromycin)
is the preferred antimicrobial for postexposure prophylaxis and
treatment of pertussis (127). Antimicrobial treatment admin-
istered in the early (catarrhal) phase of the illness can modify
the severity of the symptoms (36,128,129). An antimicrobial
generally does not modify the severity or the course of the
illness after paroxysmal cough is established but is used to
eliminate B. pertussis and halt transmission (36,127–129).
Without use of an effective antimicrobial, B. pertussis can be
recovered for 6 weeks or longer from infant patients and for
21 days or longer from adult and adolescent patients.
Detailed recommendations, indications, and schedules for
postexposure antimicrobial prophylaxis and treatment of per-
tussis have been published previously (127).
Pregnant women with pertussis near term and other house-
hold contacts with pertussis are an important source of per-
tussis for newborn infants (6,41,42,62,64,99). Antimicrobial
treatment and prophylaxis are effective in preventing trans-
mission of pertussis to neonates. A macrolide is administered
to a woman with pertussis that is acquired late in pregnancy
or shortly before delivery, her household contacts, and the
neonate. Early recognition of pertussis in a pregnant woman
is necessary to ensure the effectiveness of this approach (42,99).
Pregnancy is not a contraindication for use of erythromy-
cin, azithromycin, or clarithromycin. Erythromycin and
azithromycin are listed as FDA Category B drugs, and
clarithromycin is listed as a Category C drug (130–132).
Macrolides can interact with a variety of other therapeutic
agents, precluding concurrent use. Although macrolides can
have gastrointestional side effects (e.g., nausea and vomiting),
serious side effects (e.g., hepatic dysfunction or pseudomem-
branous colitis) are rare (127). Infants aged <1 month who
receive erythromycin are at increased risk for infantile hyper-
trophic pyloric stenosis (83,133–136). For this reason, and
because azithromycin is associated with fewer adverse effects
than erythromycin, azithromycin is the preferred antimicro-
bial for prophylaxis of neonates exposed to pertussis (127).
Infantile hypertrophic pyloric stenosis has been reported in
two preterm infants who received azithromycin for
postexposure prophylaxis (137); however, a causal association
BOX 1. CDC and the Council of State and Territorial Epidemio-
logists (CSTE) Pertussis Case Definitions*
Clinical Case Definition
• A cough illness lasting >2 weeks with one of the follow-
ing: paroxysms of coughing, inspiratory “whoop,” or
posttussive vomiting, and without other apparent cause
(as reported by a health-care professional)
Laboratory Criteria for Diagnosis
• Isolation of Bordetella pertussis from a clinical specimen,
or




— an acute cough illness of any duration associated
with B. pertussis isolation, or
— a case that meets the clinical case definition and is
confirmed by PCR, or
— a case that meets the clinical definition and is epi-
demiologically linked directly to a case confirmed
by either culture or PCR
• Probable
— a case that meets the clinical case definition, is not
laboratory confirmed by culture or PCR, and is not
directly linked epidemiologically to a laboratory-
confirmed case.
Sources: Guidelines for the control of pertussis outbreaks. Atlanta, GA:
US Department of Health and Human Services, CDC; 2006. Available
at http://www.cdc.gov/nip/publications/pertussis/guide.htm. Council of
State and Territorial Epidemiologists. CSTE position statement, 1997-
ID-9: public health surveillance control and prevention of pertussis.
Available at http://www.cste.org/ps/1997/1997-id-09.htm.
* Both probable and confirmed cases should be reported to the National
Notifiable Diseases Surveillance System (http://www.cdc.gov/epo/dphsi/
nndsshis.htm).
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between infantile hypertrophic pyloric stenosis and
azithromycin has not been established.
Immunity to Pertussis
The mechanisms of protection against pertussis are incom-
pletely understood. On the basis of studies in animals and
humans, both humoral and cellular immunity are believed to
play a complementary role (138–143). The protection that
results from B. pertussis infection or pertussis vaccines persists
for an estimated 5–10 years or more. Protection wanes over
time, leaving persons susceptible to infection or reinfection
(4,75,144–150).
Humoral Immunity to Pertussis Vaccine
Antigens
Immune responses to B. pertussis can be directed variably
against a range of pertussis toxins and antigens. No level of
antibody, presence of specific antibodies, or antibody profile
has been accepted universally as a quantifiable serologic mea-
sure of protection (139,141,151–158). Studies of parenter-
ally administered immune globulins for postexposure
prophylaxis (159,160) or for treatment of pertussis (28,161–
165) report mixed results and do not clarify the role of passive
antibodies in prevention or treatment of pertussis. By extrapo-
lation, these results do not help predict the role of transpla-
cental maternal antibodies in infant protection.
Pertussis toxin (PT), previously called lymphocytosis pro-
moting factor (LPF), is considered one of the most important
of a range of clinically relevant toxins and virulence factors of
B. pertussis (including pertactin or 69-kDa protein [PRN],
fimbriae types 2 and 3 [FIM], filamentous hemagglutinin
[FHA]) (140,142,152,157,166–169). Detoxified PT is a com-
ponent of all pertussis vaccines. The preventive efficacy of a
pediatric DTaP vaccine containing detoxified PT as the only
immunizing antigen was 71% (95% confidence interval [CI]
= 63%–78%) against classical pertussis (170). However, the
contribution to protection by anti-PT varied in analyses of
the humoral immune responses to specific vaccine antigens
when evaluated in two household studies. Elevated concen-
trations of anti-PRN and anti-FIM were associated most closely
with protection in these (152,157) and other studies (171).
Evidence of added protection from anti-FHA has been mixed
(152,156,157,172,173).
Cellular Immunity to Pertussis Vaccine
Antigens
Cell-mediated immune mechanisms clear B. pertussis from
within macrophages and other cells (52,139,174–177). In
addition to humoral immune responses, B. pertussis antigens
in acellular pertussis vaccines induce cell-mediated immune
responses (178) after primary immunization with pediatric
DTaP among infants (158,179), after booster vaccination
among children (140,141,149), and after booster vaccination
with reduced pertussis antigen content vaccines among ado-
lescents (178,180–183) and adults (183,184). Protection is
maintained among children whose antibody levels drop
below the level of detection over time (185) suggesting that
cell-mediated immunity is an important component of pro-
tection. Cell-mediated immune responses remain measurable
substantially longer than antibodies to the same antigens, par-
ticularly PT, and the cell-mediated immune responses to ini-
tial doses of pertussis vaccines are believed to correlate better
with long-term immunity than antibody responses
(140,141,149,158,178,180,181,183,185).
Prevalence of Pertussis-Specific Antibodies:
Pregnant Women and their Infants
Although the importance of antipertussis activity in sera
relative to protection remains uncertain, studies conducted
since the 1930s have determined the prevalence of antipertussis
activity in sera from mothers and infants using multiple
assays (Tables 4–8) (37,154,186–199). Detectable pertussis-
specific antibodies have been identified in unvaccinated women
without a history of pertussis (28,187,190,192), women with
a past history of pertussis (28,187,190,192), women who likely
received whole-cell pertussis vaccine during childhood
(195,196,198–200), and women with a recent history of per-
tussis (99). With the exception of women with recent pertus-
sis, the majority of pregnant women have low geometric mean
concentrations (GMCs) of anti-PT and antibodies to other
pertussis antigens (Tables 4–8) (159), consistent with gener-
ally low concentrations of antipertussis antibodies among
adults surveyed in the general population (147,201–205).
GMCs of pertussis-specific antibodies among pregnant women
typically have been low regardless of age, as demonstrated in a
predominantly (80%) African-American population reported
in 2005 (199). A 2006 study of pregnant Hispanics found
lower GMCs among adolescents than among women aged
>20 years (198).
The efficiency of maternal-fetal transfer of IgG antibodies
to pertussis-specific antigens varies; the majority of investiga-
tors report similar antigen-specific concentrations in cord or
neonatal infant sera and in maternal sera measured late in
pregnancy or at delivery (195–200), but higher concentra-
tions in cord or neonatal sera than in maternal sera have been
reported, which might indicate active transport in certain set-
tings (Tables 7 and 8) (195,197,199). In a 2005 survey of
mothers and their infants, anti-PT, anti-FHA, and anti-PRN
were detected in maternal sera from 35%, 95%, and 80% of
women, respectively, and in cord sera from 45%, 93%, and
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TABLE 4. Pertussis immune responses in unvaccinated and vaccinated pregnant women and their newborn infants, measured
by opsonocytophagic assay — selected studies,* United States, 1937–1945
No. pregnant No. women
No. mother/ women with any history Immune response to Bordetella pertussis
Study infant pairs vaccinated of pertussis Mother’s specimen Neonatal or cord specimen
Average no. leukocytes with
>20 organisms among 25 leukocytes counted
1 12 0 0 9.3 3.3
8 0 8 17.6 9.1
2 11 0 0 18.0 9.0
11 0 11 20.4 15.7
11 11 0 18.3 13.7
17 17 17 20.2 17.8
3 17 0 NR† 6.5§ 4.1§¶
4 “Moderate to strong” and “strong” responses**
No. (%) No. (%)
42 0 NR 21 (50) 4 (5)
57 57 NR 53 (93) 36 (63)
* Study 1 = Bradford WL, Slavin B. Opsono-cytophagic reaction of blood in pertussis. J Clin Invest 1937;16:825–8. Study 2 = Lichty JA Jr, Slavin B, Bradford
WL. An attempt to increase resistance to pertussis in newborn infants by immunizing their mothers during pregnancy. J Clin Invest 1938;17:613–21. Study
3 = Rambar AC, Howell K, Denenholz EJ, Goldman M, Stanard R. Studies in immunity to pertussis; an evaluation of pertussis vaccination by clinical means
and by the opsonocytophagic test. JAMA 1941;117:79–85. Study 4 = Kendrick P, Thompson M, Eldering G. Immunity response of mothers and babies to
injections of pertussis vaccine during pregnancy. Am J Dis Child 1945;70:25–8. No infants were vaccinated in these studies.
† Not reported.
§ Average is for >21 organisms per cell.
¶ Infants were all of “premature” birth, and their specimens were obtained at age 2–9 wks.
** Infant cells were obtained at age 6–29 days (median age of immunized and nonimmunized infant groups was 10 and 11 days, respectively). The opsonic
titer was calculated as the product of an arbitrary factor: 0, 1, 3, 8, and 12, respectively, for 0, 0–5, 6–20, 21–40, and >41 organisms per cell. The sum of the
products defined the “opsonic titer” as “negative to weak”(0–50), “weak to moderate” (51–100), “moderate to strong” (101–200), and “strong” (201–300).
TABLE 5. Pertussis immune responses in unvaccinated and vaccinated pregnant women and their newborn infants, by assay
used — selected studies,* United States, 1937–1943
Immune response to Bordetella pertussis
No. pregnant No. women Mother’s Neonatal or cord
No. mother/ women with any history specimen positive specimen positive
Study Assay infant pairs vaccinated of pertussis No. % No. %
1 Complement fixation 20 0 NR† 3 15 3 15
2 and 3 Complement fixation 3§ 0 0 0 0 0 0
— 29¶ 18 2 7 — —
29 29** 18 22 76 21 70
2 and 3 Mouse protection†† 3§ 0 0 0 0 2 22
— 29¶ 18 10 34 — —
29 29** 18 29 100 28§§ 100
* Study 1 = Weichsel M, Douglas HS. Complement fixation tests in pertussis. J Clin Invest 1937;15:15–22. Study 2 = Mishulow L, Leifer L, Sherwood C,
Schlesinger SL, Berkey SR. Pertussis antibodies in pregnant women. Protective, agglutinating and complement-fixing antibodies before and after vaccina-
tion. Am J Dis Child 1942;64:608–17. Study 3 = Cohen P, Scadron SJ. The placental transmission of protective antibodies against whooping cough by
inoculation of the pregnant mother. JAMA 1943;121:656–62. No infants were vaccinated in these studies.
† Not reported
§ Three maternal/infant pairs and six additional infants (nine total) were studied.
¶ Specimen collected before pregnant woman was vaccinated.
** Postvaccination.
†† Mice received intramuscular injection of 0.2 cc of patient serum 19–24 hours before peritoneal injection of a “multiple killing dose” of virulent B. pertussis.
Protection was defined by survival of >30% of mice at 7–8 days after challenge.
§§ Results were available from 28 of 29 infants.
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TABLE 6. Pertussis immune responses in unvaccinated and vaccinated pregnant women and their newborn infants, measured
by agglutinin antibody titer — selected studies,* United States, 1941–1990
No. pregnant No. women Agglutinin antibody titer to Bordetella pertussis
†
No. mother/ women with any history Mother  specimen positive Neonate or cord specimen positive
Study infant pairs vaccinated of pertussis No. % Titer No. % Titer
1–3
3§ 0 0 0 0 >1:10 0 0 >1:10
29¶ 18 4 14 >1:10
29 29** 18 27 93 >1:10 25 83 >1:10
4 142 0 NR†† 30 21 1:20–1:320 30 21 <1:10–1:160
3 2 <1:10–1:80 3 2 1:40–1:80
109 77 <1:10 109 77 <1:10
16 16 NR 16 100 >1:40 (mean: 1:320) 12 75 >1:40 (mean 1:160)
5 108 0 NR 0 0 >1:320 0 0 >1:320
54 50 Any detectable titer 34 63 Any detectable titer
6 144 0 NR NR NR NR 1 <1 >1:320
2 1 1:200
141 98 Negative
7 106 106 NR 88 83 >1:300 88 83 >1:300
8 93 0 NR 0 0 >1:320 1 2 >1:320
50 54 >1:10 22 52 >1:10
9 34 0 NR       GMT         (CI)§§         GMT          (CI)
34.0 (23.3–49.7) 34.7 (23.5–51.3)
* Study 1 = Mishulow L, Wilkes ET, Liss MM, Lewis E, Berkey SR, Leifer L. Stimulation of pertussis-protective antibodies by vaccination. A comparative
study of protective, agglutinating and complement-fixing antibodies. Am J Dis Child 1941;62:1205–16. Study 2 = Mishulow L, Leifer L, Sherwood C,
Schlesinger SL, Berkey SR. Pertussis antibodies in pregnant women. Protective, agglutinating and complement-fixing antibodies before and after vaccina-
tion. Am J Dis Child 1942;64:608–17. Study 3 = Cohen P, Scadron SJ. The placental transmission of protective antibodies against whooping cough by
inoculation of the pregnant mother. JAMA 1943;121:656–62. Study 4 = Adams JM, Kimball AC, Adams FH. Early immunization against pertussis. Am J Dis
Child 1947;74:10–8. Study 5 = Miller JJ Jr, Faber HK, Ryan ML, Silverberg RJ, Lew E. Immunization against pertussis during the first four months of life.
Pediatrics 1949;4:468–78. Study 6 = Di Sant’Agnese PA. Combined immunization against diphtheria, tetanus and pertussis in newborn infants. I. Produc-
tion of antibodies in early infancy. Pediatrics 1949;3;20–33. Study 7 = Cohen P, Schneck H, Dubow E. Prenatal multiple immunization. J Pediatr
1951;38:696–704. Study 8 = Goerke LS, Roberts P, Chapman JM. Neonatal response to DTP vaccines. Publ Health Rep 1958;73:511–9. Study 9 = Van
Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis
1990;161:487–92. No infants were vaccinated before specimens were obtained for these results.
† Number and percentage positive of number tested.
§ Three maternal infant pairs and six additional infants (nine total) were studied.
¶ Specimen collected before the pregnant woman was vaccinated.
** Postvaccination.
†† Not reported.
§§ Geometric mean titer (95% confidence interval).
81% of infants, respectively (199). Among 17 infants studied
in 1990, the half-life of transplacental maternal antibody was
36.3 days for anti-PT, 40.3 days for anti-FHA, and 55.0 days
for pertussis agglutinins (195). Transplacental maternal anti-
body was not detectable or was negligible in the majority of
infants by age 6–8 weeks (195,197) or by age 4 months (195),
consistent with the results of early studies (186). By contrast,
in a study of 23 unvaccinated Swedish infants whose mothers
had pertussis late in pregnancy, five infants had neutralizing
antibody detectable as long as 14 months and detectable anti-
PT for 5 months or longer (99).
Kinetics of Pertussis Booster Vaccination
in Nonpregnant Adults and Adolescents
The majority of adults and adolescents have had exposure
to B. pertussis, pertussis antigen–containing vaccines, or both,
and they will have a booster response to vaccination with per-
tussis antigens (184,206). A rise in antibodies is measurable
by 7 days after vaccination (207), and GMCs reach near-peak
levels by 2 weeks after booster vaccination (207–210). Anti-
body concentrations decline rapidly in the first few months
following vaccination, after which the rate of decline slows
(157,181,209,211). Anti-PT levels decline more rapidly than
anti-PRN or anti-FHA levels. Among adults who received a
booster dose of an acellular pertussis vaccine without tetanus
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TABLE 7. Antibodies to pertussis toxin (PT)* among women and their newborn infants, measured by enzyme-linked
immunosorbent assay (ELISA) — selected studies, † United States, 1990–2006 and Italy, 2003
Antibodies to pertussis toxin
IgG-specific geometric mean concentration (GMC) or titer (GMT)
and 95% confidence interval [CI] or standard deviation [SD]), EU/mL§
No. mother/ Mother at delivery Cord Cord sample to
Study infant pairs GMC or GMT CI or SD GMC or GMT CI or SD maternal sample ratio
1 34¶ 4.9 CI = 1.8–13.4 14.0 CI = 6.1–32.1 NR**
2 45†† NR NR 4.5 CI = 3.3–5.9 DNSS§§
46 NR NR 5.5 CI = 3.9–7.8 NR
3 64¶¶ 2.4 (range: 1–33) CI = 1.9–3.1 4.1 (range: 1–114) CI = 3.0–5.5 169%
4 101*** 4.4 SD = 2.6 5.6 SD = 3.0 r††† = 0.98
5 55§§§ 6.0 (range: 1–60) CI = 4.6–7.8 6.5 (range: 1–43) CI = 5.0–8.5 1.08
220 infants NR NR 8.45 (range: 1–493) CI = 7.24–9.86 NR
* Pertussis toxin (previously known as lymphocytosis promoting factor [LPF]).
† Study 1 = Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon DT. Natural history of pertussis antibody in the infant and effect on vaccine response.
J Infect Dis 1990;161:487–92. Study 2 = Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine
administered at birth. Pediatrics 2003;111:1042–5. Study 3 = Healy CM, Munoz FM, Rench MA, Halasa NB, Edwards KM, Baker CJ. Prevalence of
pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004;190:335–40. Study 4 = Gonik B, Puder KS, Gonik N, Kruger M.
Seroprevalence of Bordetella pertussis antibodies in mothers and their newborns. Infect Dis Obstet Gynecol 2005;13:59–61. Study 5 = Healy CM, Rench
MA, Edwards KM, Baker CJ. Pertussis serostatus among neonates born to Hispanic women. Clin Infect Dis 2006;42:1439–42.
§ ELISA units/milliliter.
¶ Subjects were women who delivered infants at Nashville General Hospital, Nashville, Tennessee in 1988. Assays were performed by Vanderbilt Univer-
sity School of Medicine, Nashville, Tennessee. Results were reported as antibody concentrations to LPF and not specifically as IgG antibody concentra-
tions.
** Not reported.
†† Subjects were healthy term infants in 1999 in Pavia, Italy, enrolled in a clinical trial of neonatal versus standard schedule DTaP (Biocine, Emeryville,
California). Gestational age was 37–42 weeks. The mean age of the women was 30 years (+4 years) (range: 17–37 years). Assays were performed in the
research laboratories for Pediatric Oncohematology IRCCS Policlinico San Matteo, Pavia, Italy.
§§ Difference not statistically significant.
¶¶ Predominantly (81%) white women studied during 1999–2000 in Houston, Texas (mean maternal age: 29.7 years [range: 19–42 years]; mean infant
gestational age: 39 weeks [range: 36–41 weeks]). Assays performed by Vanderbilt University School of Medicine, Nashville, Tennessee.
*** Predominantly (80%) African-American women (mean age: 26.8 years [SD = 6.8]); mean infant gestational age was 38.9 (SD = 1.4 wks); 101 maternal
sera, 103 cord sera. Assays were performed by Glaxo SmithKline Biologicals Laboratory, Rixensart, Belgium.
††† Pearson’s correlation coefficient.
§§§ Hispanic women delivering infants in 2004 in Houston, Texas; the mean maternal age (standard deviation) was 26.2 years (SD = +6 years). Assays were
performed by Vanderbilt University School of Medicine, Nashville, Tennessee.
or diphtheria toxoids, concentrations of IgG anti-PT and anti-
PRN declined 58% and 39%, respectively, after 6 months.
By 18 months after vaccination, concentrations declined 73%
and 56%, respectively (209).
Vaccinating Pregnant Women against
Pertussis
Tdap
No prelicensure studies were conducted with Tdap in preg-
nant women. In 2005, to increase understanding of the safety
of Tdap in relationship to pregnancy, both Tdap manufactur-
ers established registries to solicit voluntary reports of preg-
nant women who received Tdap during pregnancy or who
received Tdap and were determined subsequently to be preg-
nant (212,213). The main utility of the registries is to signal
the possibility and nature of any risk (214). All women who
are vaccinated with Tdap at any time during pregnancy should
be reported to the registry as early as possible during the preg-
nancy. Information from pregnancy registries differs from sur-
veillance reports, which are used to evaluate outcomes among
women when an adverse outcome of pregnancy already might
have occurred (e.g., an infant born with a birth defect) (214).
As of December 31, 2007, GlaxoSmithKline had received
five reports of pregnancy exposure to BOOSTRIX® within
28 days before conception or during any trimester of preg-
nancy, including two in the first trimester, one in the second
trimester, and two during an unknown trimester. Among the
two first-trimester exposures, one subject delivered a normal
infant at 33 weeks’ gestation, and one subject was lost to follow-
up. Of the remaining exposures, information on the outcome
of two pregnancies was not yet available, and one subject was
lost to follow-up (GlaxoSmithKline, unreported data, 2008).
As of November 23, 2007, sanofi pasteur had received 107
spontaneous reports and 47 reports from postlicensing sur-
veillance studies of exposure to ADACEL® during pregnancy.
For these 154 reports, pregnancy outcomes were 68 live
infants (including 64 term deliveries [one with a congenital
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TABLE 8. Antibodies to antigens in pertussis vaccines among women and their newborn infants, measured by enzyme-linked
immunosorbent assay (ELISA) — selected studies, United States,* 1990–2006 and Italy, 2003
IgG-specific geometric mean concentration (GMC)
and 95% confidence interval [CI] or standard deviation [SD]), EU/mL†          
Cord sample
No. mother/ Mother at delivery Cord               to maternal
Study infant pairs Antigen GMC CI or SD GMC CI or SD           sample ratio
1 45§ PRN¶ NR** NR 4.6 CI = 3.1–6.8 NR
46 PRN NR NR 4.5 CI = 2.6–6.9 NR
2 101†† PRN 12.3 SD = 2.9 10.2 SD = 3.2 r§§ = 0.96
3 64¶¶ FIM*** 13.0 (range: 2.5–869.0) CI = 9.2–18.5 20.4 (range: 2.5–1,231.0) CI = 14.0–29.6 157%
4 33††† FHA 41.4 CI = 26.1–65.6 26.8 CI = 14.5–49.4 NR
1 45 FHA NR NR 16.6 CI = 12.4–22.3 NR
46 FHA NR NR 23.4 CI = 16.1–33.5 NR
3 64 FHA 6.9 (range: 1.5–137.0) CI = 5.0–9.5 12.3 (range: 1.5–377.0) CI = 8.8–17.3 178%
2 101 FHA 26.6 SD = 3.1 32.0 SD = 3.2 r = 0.90
* Study 1 = Belloni C, De Silvestri A, Tinelli C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics
2003;111:1042–5. Study 2 = Gonik B, Puder KS, Gonik N, Kruger M. Seroprevalence of Bordetella pertussis antibodies in mothers and their newborns.
Infect Dis Obstet Gynecol 2005;13:59—61. Study 3 = Healy CM, Munoz FM, Rench MA Halasa NB, Edwards KM, Baker CJ,. Prevalence of pertussis
antibodies in maternal delivery, cord, and infant serum. J Infect Dis 2004;190:335–40. Study 4 = Van Savage J, Decker MD, Edwards KM, Sell SH, Karzon
DT . Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 1990;161:487–92.
† ELISA units/milliliter.
§ Subjects were healthy term infants in 1999 in Pavia, Italy, enrolled in a clinical trial of neonatal versus standard schedule DTaP (Biocine, Emeryville,
California). Gestational age was 37–42 weeks. The mean age of the women was 29.8 years (+4.3 years) (range: 17–37 years). Assays were performed
in the research laboratories for Pediatric Oncohematology IRCCS Policlinico San Matteo, Pavia, Italy.
¶ 69kDa protein, pertactin.
** Not reported.
†† Predominantly (80%) African-American women (mean age: 26.8 years (SD = 6.8); mean infant gestational age was 38.9 (SD = 1.4 wks); 101 maternal
sera, 103 cord sera. Assays were performed by Glaxo SmithKline Biologicals Laboratory, Rixensart, Belgium.
§§ Pearson’s correlation coefficient.
¶¶ Predominantly (81%) white women studied during 1999–2000 in Houston, Texas (mean maternal age: 29.7 years [range: 19–42 years]; mean infant
gestational age: 39 weeks [range: 36–41 weeks]). Assays performed by Vanderbilt University School of Medicine, Nashville, Tennessee.
*** Fimbrial proteins.
††† Subjects were women who delivered infants at Nashville General Hospital, Nashville, Tennessee in 1988. Assays were performed by Vanderbilt Univer-
sity School of Medicine, Nashville, Tennessee. Results were reported as antibody to filamentous hemagglutinin (FHA), not specifically to IgG antibody
concentrations.
anomaly] and four preterm deliveries [one at 28 weeks after
complications of pregnancy, labor, and delivery; two at 35
weeks for preeclampsia; and one at 35 weeks for breech pre-
sentation]); three spontaneous abortions (at 9, 51, and 99
days postvaccination); three induced abortions; and one fetal
demise (at 35 days postvaccination). For 32 reports, either
the outcome of pregnancy was unknown or the patient was
lost to follow-up, and for 47 reports, information on out-
come of pregnancy was not yet available (sanofi pasteur,
unreported data, 2008).
A retrospective survey of 4,524 health-care personnel vacci-
nated in a mass vaccination campaign conducted in 2006 pro-
vides additional information regarding adverse reactions in
pregnant women within 14 days of receiving Tdap
(ADACEL®) (215,216). Pregnancy was not an exclusion cri-
terion for Tdap; 24 health-care personnel who received Tdap
identified themselves as pregnant at the time of vaccination.
Among 2,676 (59%) survey respondents, 1,792 (67%)
received Tdap at an interval of >2 years after their most recent
dose of Td; 17 of these respondents identified themselves as
pregnant. Adverse reactions reported by the 17 pregnant
women were compared with reactions reported by 472 non-
pregnant female personnel aged 18–44 years. The frequencies
of injection-site pain, redness, and swelling of moderate to
severe intensity were not greater among the pregnant women
than among the nonpregnant women. Three of the pregnant
women reported feeling “feverish” after receiving Tdap. None
of the 17 pregnant women reported seeking nonroutine medi-
cal attention for the adverse reaction (215,216). Among the
pregnant women vaccinated with Tdap, results of the outcome
of pregnancy were known for 10 women; no pregnancy resulted
in premature birth or abnormality in the infant when assessed
shortly after birth (Elizabeth A. Talbot, Dartmouth College,
Lebanon, New Hampshire, personal communication, 2007).
Whole-Cell Pertussis Vaccine
Five clinical trials conducted during the 1930s and 1940s
evaluated vaccinating pregnant women with whole-cell per-
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tussis vaccine as a strategy to increase the levels of maternal
pertussis-specific antibodies transferred to their infants via the
placenta (Table 9) (186,189,190,192,193,217). The protec-
tive efficacy of the vaccine against pertussis in the women was
not a consideration. Whole-cell pertussis vaccine was prepared
from sterile extracts of killed B. pertussis. To maximize the
passive transfer of maternal antibody, pregnant women were
vaccinated with 2–6 doses at 1- to 2-week intervals during the
third trimester.
Local reactions to vaccination in the pregnant women were
common, some of which were severe. Systemic reactions were
uncommon, adverse pregnancy outcomes were not reported
(Table 9) (190,192,193,217).
The majority of women had substantial rise in titer to
B. pertussis antigens in postvaccination sera compared with
prevaccine titers (Tables 4–6) (186,189,190,192,193,217).
Neither history of pertussis (190,192) nor preexisting titers
of antibodies in the women correlated with maternal titers
after vaccination (193). The majority of infant antibody titers
were lower than (186) or similar to maternal titers
(37,150,186,187,189–193). Infant titers exceeded maternal
titers in certain cases although higher titers might have been
within the range of assay variation (37,186–191,193).
In subsets of infants in two studies, the duration of detect-
able transplacental pertussis antibodies was followed among
unvaccinated infants (186,217). The mothers in both studies
TABLE 9. Clinical trials in pregnant women using killed, whole-cell pertussis vaccines — selected studies*, United States,
1938–1951
No.                 Vaccine
pregnant Total dose (cfu† Interval
women  of killed Bordetella Inactivation between
Study vaccinated pertussis) (manufacturer) Timing Doses (route) doses Adverse reactions
* Study 1 = Lichty JA Jr, Slavin B, Bradford WL. An attempt to increase resistance to pertussis in newborn infants by immunizing their mothers during pregnancy. J Clin Invest
1938;17:613–21. Study 2 = Cohen P, Scadron SJ. The placental transmission of protective antibodies against whooping cough by inoculation of the pregnant mother. JAMA
1943;121:656–62. Study 3 = Cohen P, Scadron SJ. The effects of active immunization of the mother upon the offspring. J Pediatrics 1946;29:609–19. Study 4 = Mishulow L,
Wilkes ET, Liss MM, Lewis E, Berkey SR, Leifer L. Stimulation of pertussis-protective antibodies by vaccination. A comparative study of protective, agglutinating and complement-
fixing antibodies. Am J Dis Child 1941;62:1205–16. Study 5 = Mishulow L, Leifer L, Sherwood C, Schlesinger SL, Berkey SR. Pertussis antibodies in pregnant women. Protective,
agglutinating and complement-fixing antibodies before and after vaccination. Am J Dis Child 1942;64:608–17. Study 6 = Kendrick P, Thompson M, Eldering G. Immunity
response of mothers and babies to injections of pertussis vaccine during pregnancy. Am J Dis Child 1945;70:25–8. Study 7 = Adams JM, Kimball AC, Adams FH. Early
immunization against pertussis. Am J Dis Child 1947;74;10–18. Study 8 = Cohen P, Schneck H, Dubow E. Prenatal multiple immunization. J Pediatr 1951;38:696–704.
† Colony forming units.
§ Killed phase I Bordetella pertussis diluted to 10 billion cfu per 1.0 cubic milliliter (Source: Saur LW. Immunization with Bacillus pertussis vaccine. JAMA 1933;101:1449–53).
¶ Subcutaneous.
** Intramuscular.
†† No premature births occurred, and no postpartum complications were attributed to vaccination.
§§ Not reported.
¶¶ Two pertussis vaccine preparations were used during the trials. The number of subjects allocated to each vaccine group, and the details of the protocol were not reported. Certain
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had received 3 doses of whole-cell pertussis vaccine during
the third trimester. The mean of the agglutinin titers among
13 infants in one study dropped from 1:160§ at birth to 1:80
at age 2 months; titers no longer were measurable at “a few
months of age” (186). Of 36 infants with high agglutinin
titers at birth in the other study, 16 (44%) had titers of >1:300
at age 3 months. None of 9 infants followed to age 6 months
had a titer of 1:300 (217).
Infant Protection by Transplacental
Maternal Antibody
The role of transplacental maternal antibody in infant pro-
tection against pertussis remains uncertain. Prevaccine era
observations concluded that infants have no “congenital
immunity” and are susceptible to pertussis from the “day of
birth,” with the possible exception of an infant whose mother
had pertussis during pregnancy (35,189,190,192,193,219).
Transplacental maternal antibodies might explain the smaller
proportion of infant pertussis deaths observed in the first
month of life compared with the second and third months of
life (Figure 1) (35,45). An alternative explanation might be
that parents avoid exposing newborn infants to ill contacts
(99,219).
Two retrospective surveys were conducted after early vac-
cine trials in pregnant women to assess infant protection
(217,220). In one survey conducted during the 1940s, a sub-
set of 100 (59%) of 170 women who received 6 doses of whole-
cell pertussis vaccine during the third trimester and 100 women
who were not vaccinated were questioned regarding pertussis
in their infants during the first year of life. During the first 6
months of life, eight exposures (three of which were “close
exposures”) and no cases of pertussis were reported among
infants whose mothers had been vaccinated, and six expo-
sures and three cases of infant pertussis were reported among
infants whose mothers had not been vaccinated. From age
6–11 months, two cases of infant pertussis were reported in
each group (220). In a second survey by the same investiga-
tors, a subset of 66 (62%) of 106 women who received 3 doses
of whole-cell pertussis vaccine during the third trimester
reported two exposures and no case of pertussis among their
infants during the first 6 months of life (217). The results of
these surveys suggested that high concentration of transpla-
cental pertussis antibodies might provide a degree of infant
protection against pertussis in the first 6 months of life
(217,220).
Inhibitory Effect of Transplacental
Maternal Antibody on Infant
Immunization
Transplacental maternal antibodies to pertussis antigens can
interfere with the infant’s response to active immunization
with the pertussis components of pediatric DTP and pediat-
ric DTaP (221). A proposed mechanism for the interference
with pertussis and other vaccine antigens is maternal anti-
body binding to vaccine antigens, masking the vaccine anti-
gens from the infant’s B cells. Infant antigen-presenting cells
also might take up maternal antibody-vaccine antigen com-
plexes stimulating selective T-cell responses without humoral
immune responses to the vaccine antigens (221–223). The
concentrations and specificities of the maternal antibodies for
vaccine-antigen epitopes contributes to the degree of interfer-
ence (221,223–225). The inhibitory effect of transplacental
maternal antibody can be detectable for a few weeks or for
more than 1 year (221,222,224–228). As transplacental
maternal antibody declines over time, a threshold is reached
when the infant’s immune system responds to vaccine anti-
gens in subsequent doses. In theory, the threshold concentra-
tion of residual maternal antibody could be lower than the
concentration of antibody needed for infant protection, but
this concentration is not known for pertussis. In this setting,
a theoretical window of “relative susceptibility” exists for the
infant until the infant mounts a humoral immune response
to a subsequent dose of vaccine (222,229).
Interference with Pertussis Responses to
Pediatric DTP
Substantially lower concentrations of infant IgG anti-PT
result after 3 doses of pediatric DTP among infants with “high”
(variably defined) prevaccination levels of maternal IgG anti-
PT, than among infants with “low” or no measurable
prevaccination level of maternal IgG anti-PT (195, 230–233).
The post-dose 3 concentrations of infant anti-PT in one study
were 28% or 56% lower with each doubling of the concentra-
tion of transplacental maternal anti-PT, respectively, for the
two DTP products studied (p <0.05) (233). The reductions
in post–dose 3 concentrations also were significant for anti-
FIM (18% lower) and agglutinins (15% lower) for one DTP
product, and for anti-FHA (16% lower) for the other DTP
product, with each doubling of the concentration of the spe-
cific transplacental maternal antibodies (p <0.05) (233).
Interference with Pertussis Responses to
Pediatric DTaP
Transplacental maternal IgG anti-PT might interfere less
with infant responses after 3 doses of pediatric DTaP than§ Titers of >1:320 have been reported to correlate with protection in some
studies (218).
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after pediatric DTP (195,196,230,233). The percentage
decrease in post–dose 3 infant antibody response with each
doubling of the concentration of maternal antibodies was 3%
for anti-PT (not statistically significant), but was 13% for anti-
PRN, 17% for anti-FIM, 10% for agglutinins, and 8% for
anti-FHA (all statistically significant; p <0.05) when results
from several DTaP products were combined in one study
(233). The difference between interference by maternal anti-
body with infant responses to DTP and DTaP might result
from the higher content of pertussis-specific antigens in pedi-
atric DTaP than in pediatric DTP relative to the concentra-
tion of transplacental maternal antibody (159,222). In
addition, the maternal antibodies induced by the mothers’
childhood DTP vaccinations might have less specificity for
the pertussis vaccine antigens in acellular pertussis vaccines
(222,234–236).
Noninterference with Pertussis Cellular
Immune Responses to Pediatric DTP or DTaP
Infants who have relatively poor humoral immune responses
to active immunization with whole-cell or acellular pertussis
vaccine in the presence of inhibitory concentrations of trans-
placental maternal antibody have evidence of T-cell priming
for booster (anamestic) responses (158,237). Protection against
pertussis in T-cell primed infants in the absence of specific
humoral antibodies has not been established (158,238–241).
Lactation
Existing data do not provide evidence that human colostral
pertussis antibodies contribute to infant protection, although
pertussis-specific antibodies present in the mother are found
in colostral milk (186,190,242). Protection studies in animal
models suggest human and animal colostral-derived pertussis
antibodies can protect animals when the antibodies are
absorbed or injected parenterally (243–245); however, the rel-
evance of these studies for human infants is uncertain
(190,246,247). Human breast milk antibodies do not enter
the human neonatal circulation from the intestine in substan-
tial amounts. In contrast, infant pigs, horses, ruminants, dogs,
and cats acquire the majority of neonatal protection through
intestinal uptake of colostral antibodies (245,248–250).
Maternal antibodies in human milk do not interfere with the
infant immune response to pediatric vaccines (23).
Tetanus
Tetanus is caused by Clostridium tetani spores, which are
ubiquitous in the environment. Spores enter the body through
disrupted skin or mucus membranes. When inoculated into
oxygen-poor sites (e.g., necrotic tissue or wounds), C. tetani
spores germinate to vegetative bacilli that elaborate tetano-
spasmin, a potent neurotoxin. More than 80% of cases of
tetanus are of the generalized syndrome; the remaining cases
are localized or cephalic. Persons with generalized cases typi-
cally have trismus (lockjaw), followed by rigidity and painful
contractions of the skeletal muscles that can impair respira-
tory function. Glottic spasm, respiratory failure, and auto-
nomic instability can result in death. The onset of tetanus
typically is within 7 days of the injury (range: 0–112 days)
The course of tetanus is up to 4 weeks or longer, followed by
a prolonged period of convalescence (251,252).
Obstetric and Neonatal Tetanus
Obstetric tetanus is defined as tetanus during pregnancy or
with onset within 6 weeks after the termination of pregnancy
(253). Obstetric tetanus occurs after contamination of wounds
or abrasions during pregnancy or after unclean deliveries or
abortions. In a review covering 1941–1990, an estimated
65%–80% of cases of obstetric tetanus occurred in the puer-
peral or postpartum period; the majority of the other cases
occurred after surgical or spontaneous abortions (254).
Obstetric tetanus has the highest mortality when the incu-
bation period is short and respiratory complications are present
(255). Cases can be complicated by gram-negative sepsis (256).
Case-fatality rates vary (range: 16%–>50%); higher fatality
rates are reported from places where access to medical inten-
sive care is limited (255,257,258). Case-fatality rates histori-
cally have been higher for postabortal than for postpartum
obstetric tetanus (254).
Neonatal tetanus (tetanus neonatorum) is associated with
contamination of the umbilical stump. In nearly all cases of
infant tetanus, onset occurs in the first month of life. Symp-
toms commonly begin at 3–14 days of life and are character-
ized by increasing irritability and difficulty feeding. Signs of
neonatal tetanus are similar to tetanus in older age groups.
Case-fatality rates vary (range: 10%–100%) (252,259).
Infants who survive can have residual neurologic injury (e.g.,
cerebral palsy and psychomotor retardation) (252).
Burden
Tetanus is a nationally notifiable disease in the United States
(260). In 2006, a total of 41 cases were reported. No cases
occurred among women aged 15–19 years or those aged
30–39 years. One case occurred among women aged 20–29
years, and three cases occurred among women aged 40–49
years. None of the women died. During 1972–2006, case
reporting forms did not collect information regarding preg-
nancy; however, no case of obstetric tetanus was identified
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among more than 1,000 reports to NNDSS (CDC, unpub-
lished data, 2006). In 1999, tetanus-specific coding became
available in CDC’s mortality database; no case of tetanus-
associated obstetric death was reported through 2005, the most
recent year for which data are available (CDC, unpublished
data, 2008).
During the 1950s, approximately 100 neonatal tetanus
deaths were reported annually in the United States, and neo-
nates comprised more than one third of tetanus deaths in all
age groups (261,262). During 1972–2006, the cumulative
number of reported neonatal tetanus cases decreased to 32;
the most recent cases were reported in 1989, 1995, 1998, and
2001 (263). Among these 32 neonatal cases, 27 (84%) births
occurred in a nonhospital setting; 30 of 31 mothers with avail-
able history reported never having received a dose of tetanus
toxoid vaccine (264–266; CDC, unpublished data, 2006).
Diagnosis and Treatment
The diagnosis of tetanus is clinical and is supported by a
compatible setting, immunization history, and exclusion of
other possible diseases. Anaerobic cultures of tissues or aspi-
rates for C. tetani typically are not positive. Low or undetect-
able levels of serum antitoxin at the time of onset are
compatible with the diagnosis of tetanus, but higher levels of
antitoxin do not exclude the diagnosis (252,267). Electromyo-
graphy might aid in the diagnosis of certain cases (268). Post-
partum eclampsia, which typically occurs within the first few
days after delivery, was the most important disease in the dif-
ferential diagnosis in community-based studies (254).
Treatment of tetanus is directed at neutralizing unbound
toxin with administration of human tetanus immune globu-
lin, removing the source of infection through debridement,
and use of an antimicrobial (e.g., metronidazole). The con-
trol of rigidity and spasms, attendant respiratory and auto-
nomic dysfunction and their complications, and maintaining
nutrition require careful and sustained attention that is best
provided in intensive-care settings with specialty consultation
(251,252,269).
Immunity to Tetanus
The level of antitoxin that protects against obstetric and
neonatal tetanus can vary with the wound characteristics, the
degree of contamination, the specificity of the antitoxin, and
the type of assay employed to measure the antitoxin level (270).
The minimum level of antitoxin correlating with protection
is 0.01 IU/mL as measured by in vivo neutralization assay. An
antitoxin concentration at >0.1 IU/mL is the preferred corre-
late of protection based on the results of other assays (e.g.,
enzyme-linked immunoabsorbant assay [ELISA]), and
because higher concentrations of antitoxin might be neces-
sary to protect in certain circumstances (252,270). The
serum level of tetanus antitoxin achieved in response to vacci-
nation is determined by the number of doses of tetanus tox-
oid, the type of tetanus toxoid administered (adjuvanted
toxoid, which is more immunogenic, has replaced fluid tox-
oid), the interval since the most recent dose, and individual
variation in the response to vaccination (270).
Deferring Td During Pregnancy
to Substitute Tdap in the Immediate
Postpartum Period
Ensuring maternal and neonatal tetanus protection as part
of prenatal care is a priority for women who are due for a
recommended decennial tetanus and diphtheria toxoids
booster dose. For women who have not received a dose of
Tdap previously, administering Td during pregnancy, followed
in a few months by Tdap postpartum, theoretically could
increase the risk or severity of adverse reaction, which typi-
cally is local. Moderate to severe local reactions have been
associated with high levels of tetanus and diphtheria antitoxin
(see Interval Between Td and Tdap). In these women, defer-
ring the Td booster during pregnancy to substitute Tdap in
the immediate postpartum period may be considered to boost
protection against pertussis as well as tetanus and diphtheria.
The majority of women of childbearing age who have lived in
the United States since infancy or childhood have received
4–5 infant and childhood doses of tetanus toxoid with pedi-
atric DTP or DTaP and >1 booster dose of Td (or tetanus
toxoid without diphtheria toxoid [TT]) in accordance with
national recommendations (1,2,271). The recommended
schedule of vaccination to prevent tetanus is intended to main-
tain levels of antitoxin considerably higher than the minimum
level required for protection against the majority of cases of
tetanus, including protection among persons with intrinsi-
cally lower responses to vaccination (1,2,252,271–273).
In 2004, women aged 15–39 years accounted for 97% of
all births in the United States (3). Data from a population-
based serosurvey conducted nationwide in the United States
during 1988–1994 documented tetanus antitoxin concentra-
tions at >0.15 IU/mL among >80% of women aged 12–39
years (274,275). The proportion of women with antitoxin at
>0.15 IU/mL declined with increasing age to 62% among
women aged 40–49 years (274,275). Slightly lower prevalence
of this titer was found among women aged 20–59 years who
were not born in the United States (276). A 1999–2000 study
evaluated 2,134 adult patients in an emergency department
for wound management and measurement of their antitoxin
titer (277). Antitoxin concentrations of >0.15 IU/mL were
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present among 1,051 (95%) of 1,106 adults aged 18–39 years.
Among adults of all ages studied, approximately 95% of those
with up-to-date vaccination histories and approximately 86%
of those whose vaccinations were not up-to-date had anti-
toxin titers >0.15 IU/mL. The rates of a protective titer were
lower for immigrants, persons with less education, and per-
sons aged >70 years (277). Limitations of these studies are
that one study did not report any connection between vacci-
nation histories and antitoxin concentrations (274–276), and
the other study included subjects who might not be represen-
tative of the U.S. population (277). However, when combined
with the small number of tetanus cases among women of child-
bearing age in the United States, these studies suggest that
when pregnant women have previously received the recom-
mended schedule of tetanus and diphtheria toxoids vaccina-
tions, a routine decennial Td booster during pregnancy
typically can be deferred so Tdap can be substituted at deliv-
ery or before discharge from the hospital or birthing center.
Vaccinating to Prevent Obstetric
and Neonatal Tetanus
Success in preventing obstetric and neonatal tetanus relies
on antitoxin being present at delivery (254). In countries where
access to childhood vaccines is limited, neonatal tetanus con-
stitutes a major cause of infant mortality; during 1978–1985,
an estimated 800,000 neonatal tetanus deaths occurred
annually worldwide (278). In 1974, worldwide elimination
of neonatal tetanus (less than one case per 1,000 live births)
through vaccine initiatives became a major focus of the
Expanded Program of Immunization of the World Health
Organization (WHO) (259,279). The initiative promoted
clean deliveries and tetanus toxoid vaccination for pregnant
women. Nonpregnant women of childbearing age also were
targeted for at least 3 doses of tetanus toxoid vaccine in supple-
mental immunization activities.
The strategy of targeting pregnant women for vaccination
to prevent neonatal tetanus was based on reports published in
the 1960s concerning two vaccine trials that demonstrated
that >2 doses of tetanus toxoid administered during pregnancy
were >95% effective in preventing neonatal tetanus (Table 10)
(280,281). Subsequent studies confirmed that 3 doses of alu-
minum phosphate-adjuvanted tetanus toxoid (rather than fluid
toxoid) administered during pregnancy induced antitoxin lev-
els that would protect the mother and prevent neonatal teta-
nus for >10 years. Adjuvanted vaccine also lowered the rates
of local reactions in pregnant women (282–284).
Although the burden of obstetric tetanus has not been char-
acterized as well as the burden of neonatal tetanus, the annual
worldwide burden of obstetric tetanus deaths has been esti-
mated at 15,000–30,000, accounting for approximately 5%
of all maternal deaths in the 1990s (254,259). In April 2006,
WHO’s Strategic Advisory Group of Experts (SAGE) reported
on the success of the maternal and neonatal tetanus elimina-
tion initiatives and the plan to transition from vaccination
goals for women of childbearing age to universal tetanus con-
trol, to be achieved through sustained high coverage with
pediatric DTP starting in infancy and childhood and booster
doses to prevent tetanus throughout life (259,285,286).
Safety of Tetanus Vaccination During
Pregnancy
No evidence suggests that adverse outcomes for a mother
or fetus increase after tetanus toxoid is administered to a preg-
nant woman (1,2,23). Tetanus toxoid administered during
any trimester of pregnancy was evaluated for association with
congenital abnormalities at birth during 1980–1994 in
Budapest, Hungary. The rate of tetanus toxoid vaccination
among 21,563 mothers of infants with congenital abnormali-
ties was not significantly different than the rate of tetanus
toxoid vaccination among 35,727 mothers of infants who were
normal (0.12% and 0.09%, respectively; p = 0.39) (287). In a
similar study conducted in nine countries in South America
starting in 1977, approximately one half of the women had
received tetanus toxoid during the first trimester of pregnancy.
The rate of early tetanus toxoid vaccination among the moth-
ers of 34,293 newborns with congenital malformations (9.2
[CI = 8.2–10.3] per 1,000 mothers) was not substantially dif-
ferent than the rate among the mothers of 34,477 newborns
who were normal (7.6 [CI = 6.6–8.5] per 1,000 mothers) (288).
Infant Protection by Transplacental
Maternal Antibody
Tetanus toxoid is one of the most immunogenic protein
antigens in any vaccine. Administration of 2 doses of tetanus
toxoid to pregnant women at least 4–6 weeks before delivery
stimulates antitoxin that protects the mother and readily crosses
the placenta, thereby protecting the newborn against tetanus
when the risk is highest (289). Pregnant women who receive a
booster dose of tetanus toxoid have a measurable immune
response within 5 days and a peak response in <2 weeks. The
response to vaccination might be slower after a first (primary)
dose or when the interval after the most recent booster dose is
long (252,272). Placental transport of maternal IgG antitoxin
is efficient; cord blood levels generally are similar to maternal
levels (290,291). After the neonatal period, the infant is at
little risk for tetanus until becoming self-mobile, typically at
an age when sustained protection has been induced by 3
infant doses of pediatric DTP or DTaP (252).
Vol. 57 / RR-4 Recommendations and Reports 21
Inhibitory Effect of Transplacental
Maternal Antibody on Infant
Immunization
Transplacental maternal tetanus antitoxin can interfere with
the infant response to active immunization after up to 3 doses
of tetanus toxoid (e.g., in pediatric DTP, DTaP, or DT)
(222,230,292–297). Certain studies (296,297), but not all
(298), indicate that antitoxin inhibits the response to tetanus
toxoid after vaccination with Haemophilus influenzae type b
polysaccharide conjugated to tetanus toxoid. An age-
accelerated schedule results in further decrease in infant
responses in the presence of maternal antitoxin (295). When
levels of transplacental maternal antitoxin wane sufficiently,
infants respond to subsequent doses of vaccine
(229,293,294,299–301). T-cell priming for a booster response
is not substantially affected by maternal antitoxin (222,302,
303). Typically, infants respond to the second dose of tetanus
toxoid–containing vaccine with a protective level of antitoxin,
even when the initial levels of maternal antitoxin are high;
3 doses of tetanus toxoid are required to achieve antitoxin
concentrations that persist above protective levels (292,304).
Lactation
No substantial difference in the infant immune response to
tetanus toxoid (in DTP) has been identified with consumption
of human milk compared with consumption of cow milk (305).
Diphtheria
Respiratory diphtheria is an acute, severe infection caused
by strains of Corynebacterium diphtheriae that produce diph-
theria toxin. Rarely, toxin-producing strains of C. ulcerans cause
a diphtheria-like illness (306). Respiratory diphtheria is char-
acterized by a grayish-colored adherent membrane on the
pharynx, palate, or nasal mucosa that can obstruct the airway
with fatal outcome. The disease can be complicated by toxin-
mediated cardiac, neurologic, or renal dysfunction. Case-
fatality rates are >10% (307,308).
Obstetric and Neonatal Diphtheria
Respiratory diphtheria (309–312) or vulvovaginal infection
(313,314) can occur during any trimester of pregnancy, at
term, or in the postpartum period. The mortality rate of
obstetric respiratory diphtheria is high (estimated at 50%)
without infusion of diphtheria antitoxin, even with tracheo-
stomy or intubation, and is accompanied by fetal loss or pre-
mature birth in approximately one third of survivors. Early
treatment with serum diphtheria antitoxin improves survival
and pregnancy outcomes, although complications of the dis-
ease might require prolonged supportive care (309–312). Post-
partum women with respiratory diphtheria can transmit
C. diphtheriae to their neonates (310).
Burden
Respiratory diphtheria is a nationally notifiable disease in
the United States. Rare cases occur in the United States after
infection with diphtheria toxin–producing strains of
C. diphtheriae or other corynebacteria (315,316). During
1998–2006, seven cases of respiratory diphtheria were reported
to CDC. The most recent culture-confirmed adult case of
respiratory diphtheria caused by C. diphtheriae was reported
in 2000, and an adult case of respiratory diphtheria caused by
C. ulcerans was reported in 2005 (306). The risk for diphthe-
ria can be increased during travel to areas in which diphtheria
is endemic; a list of these areas is available at http://www.cdc.
gov/travel/default.aspx. Diphtheria also can be acquired from
persons with imported cases or from carriers (i.e., asymptom-
atic persons who are colonized with toxin-producing
C. diphtheriae) (315,316).
TABLE 10. Number and percentage of neonatal tetanus cases, by number of doses of tetanus toxoid vaccine administered to
the pregnant woman —  selected studies, New Guinea, 1961 and Columbia, 1966
Study*              Trial design                                   Vaccine      No. of doses
0–1 dose 2 doses 3 doses
No. (%) No. (%) No. (%)
1 62 villages Fluid toxoid 16/160 (10.0) 8/234 (3.4) 1/175 (0.6)
0 dose 1 dose 2–3 doses
No. (%) No. (%) No. (%)
2 Double-blind, controlled Al PO3-adsorbed toxoid 46/617 (7.5) 9/224 (4.0) 0/341  (0)
* Study 1 = Schofield FD, Tucker VM, Westbrook GR. Neonatal tetanus in New Guinea: effect of active immunization in pregnancy. Br Med J 1961;2:735–9.
Study 2 = Newell KW, Dueñas Lehmann AD, LeBlanc DR, Garces Osorio NG. The use of toxoid for the prevention of tetanus neonatorum: final report of
a double-blind controlled field trial. Bull World Health Org 1966;35:863–71.
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Diagnosis and Treatment
The diagnosis of diphtheria is confirmed by isolation of
C. diphtheriae in culture of the adherent membrane and by
testing the isolate for toxin production (317). The mainstay
of treatment in respiratory diphtheria is early administration
of diphtheria antitoxin (equine), which is available to physi-
cians in the United States from CDC through an FDA-
Investigational New Drug protocol (24-hour telephone,
770-488-7100). Additional information is available at
http://www.cdc.gov/vaccines/vpd-vac/diphtheria/dat/dat-
main.htm. No human-derived serum diphtheria antitoxin is
available. Antibiotics are administered to limit transmission and
to prevent continuing production of diphtheria toxin (318).
Prompt reporting of suspect cases, investigation, culture, and
antimicrobial prophylaxis of contacts and immunization of the
affected community (317,318) is of critical importance.
Because respiratory diphtheria does not always confer protec-
tion against future illness, patients should complete active
immunization with diphtheria toxoid after recovery (286).
Diphtheria Immunity
Protection against respiratory diphtheria is predominantly
from IgG antibody to diphtheria toxin (antitoxin) induced
after infection with toxin-producing C. diphtheriae or after
vaccination with diphtheria toxoid. In areas with little or no
endemic exposure to toxin-producing C. diphtheriae, periodic
vaccination is required to maintain immunity (237,286,307,
319–321). Although the immune responses to infection and
vaccination vary, antitoxin concentrations of >0.1 IU/mL
typically are considered protective. Concentrations of 0.01
IU/mL–0.1 IU/mL might provide protection against severe
disease; concentrations <0.01 IU/mL do not protect against
diphtheria (286,307,322).
Td Booster During Pregnancy
for Diphtheria Protection
Data from a national population-based serosurvey con-
ducted during 1988–1994 that evaluated the prevalence of
immunity to diphtheria (defined as a diphtheria antitoxin
concentration of >0.1 IU/mL) among women in the United
States determined immunity to diphtheria to be lower than
immunity to tetanus (see Tetanus: Deferring Td During Preg-
nancy to Substitute Tdap in the Immediate Postpartum
Period). The prevalence of immunity to diphtheria decreased
with increasing age (77% among women aged 12–19 years,
74% among women aged 20–29 years, 65% among women
aged 30–39 years, and <45% among women aged >40 years)
and with birth outside the United States or less formal educa-
tion (274,276).
Vaccinating Pregnant Women, Infant
Protection by Transplacental Antibody
Diphtheria toxoid vaccine trials conducted among pregnant
women in the 1940s demonstrated quantitative increases in
diphtheria antitoxin after the women were vaccinated.
Maternal antitoxin was transferred efficiently to the fetus
(217,226,320,323,324). Several studies indicate transplacen-
tal maternal antitoxin provides newborn infants with protec-
tion against diphtheria at birth if their mother is immune
(226,250,321,325).
Safety
The safety of diphtheria toxoid (without tetanus toxoid)
vaccination in pregnant women was examined during the
1970s (326). After diphtheria toxoid was administered dur-
ing the first 4 months of pregnancy, 75 mother-child pairs
were followed for malformations until the child reached age 7
years. Although the number of vaccinated pregnant women
studied was small, the risk for malformations in their children
was lower than the risk among children in a much larger group
of mother-child pairs in which the women were not vacci-
nated with diphtheria toxoid during pregnancy (survival- and
race-standardized relative risk: 0.88) (327).
Inhibitory Effect of Transplacental
Maternal Antibody on Infant
Immunization
Transplacental maternal diphtheria antitoxin concentrations
of <0.1 IU/mL can interfere with primary diphtheria toxoid
immunization in infancy (237,292,321,328–331). The
duration of interference is affected by the concentration of
maternal antitoxin, the formulation and toxoid content of the
infant vaccine (e.g., the limit of flocculation [Lf ] units of diph-
theria toxoid, aluminum hydroxide-adsorbed, or fluid prepa-
ration), and the length of the interval between doses
(229,237,292,293,295,299,321,328–331). Infants typically
respond with increases in antitoxin after 2 doses of high-
content diphtheria toxoid vaccine when maternal antitoxin
concentrations are 0.1 IU/mL in cord sera but not until after
>3 infant doses of high-content diphtheria toxoid vaccine when
maternal antitoxin concentrations are >1.0 IU/mL in cord
sera (225,229,292,299,321,329,331,332). When infants
receive subsequent doses of diphtheria toxoid, the responses
are rapid, often within 2 weeks (330), suggesting that T-cell
priming occurs in the absence of an infant antibody response
to previous doses of vaccine (229,237,324,329,330).
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Lactation
Consumption of human milk does not affect the infant
immune response to diphtheria toxoid–containing vaccines
(292,332). Ingestion of colostrum from an immune mother
does not result in an increase in the concentration of diphthe-
ria antitoxin in infant sera (250).
Adult and Adolescent Acellular
Pertussis Combined with Tetanus
and Reduced Diphtheria Toxoids
(Tdap) Vaccines and Tetanus
and Reduced Diphtheria
Toxoids (Td) Vaccines
Both Tdap vaccines used in the United States (ADACEL®
and BOOSTRIX®) were licensed on the basis of clinical trials
in the United States demonstrating immunogenicity not infe-
rior to that of U.S.-licensed Td (333,334) and the pertussis
components of pediatric DTaP made by the same manufac-
turer and an acceptable safety profile (212,213). Adsorbed
Td products for adults and adolescents have been licensed in
the United States since the 1950s (335). Components of these
and other diphtheria and tetanus toxoids–containing vaccines
have been listed (Table 1) and are available at http://www.fda.
gov/cber/vaccines.htm.
In prelicensure trials, data on local and systemic adverse
events were collected using standard diaries for the day of vac-
cination and the next 14 consecutive days (212,213,336–338).
The efficacies of the tetanus toxoid and the diphtheria toxoid
components of Tdap were inferred from the immunogenicity
of the antigens in Tdap compared with Td using established
serologic correlates of protection in sera obtained before and
approximately 1 month after vaccination. Because no well-
accepted serologic or laboratory correlate of protection is avail-
able for pertussis, the efficacy of the pertussis components of
Tdap was inferred using a serologic bridge (comparison) to
the immune response to vaccine antigens among infants who
received 3 doses of pediatric DTaP (made by the same manu-
facturer) during clinical efficacy trials for pertussis during the
1990s (339). The efficacy against pertussis of an acellular per-
tussis vaccine without tetanus and diphtheria toxoids was 92%
(CI = 32%–99%) for adults and adolescents in a randomized,
controlled trial (340); these results were not considered in the
evaluation of Tdap for licensure in the United States.
Selected results from the prelicensure trials are summarized
below. Additional information can be found in previous ACIP
statements discussing use of Tdap among adults and adolescents
and in the package labels of the specific products (1,2,212,213).
ADACEL®
ADACEL® contains the same tetanus toxoid, diphtheria
toxoid, and five pertussis antigens as those in DAPTACEL®
(pediatric DTaP, also made by sanofi pasteur), but ADACEL®
is formulated with reduced quantities of diphtheria toxoid
and detoxified PT. Prelicensure trials in the United States evalu-
ated the immunogenicity and the safety of ADACEL® among
adults aged 18–64 years and among adolescents aged 11–17
years, randomized to receive a single dose of ADACEL® or a
single dose of Td made by the same manufacturer (Table 1)
(1,2,212,333). Pregnant women were excluded.
Immunogenicity
Tetanus and Diphtheria Toxoids. The rates of sero-
protection and booster response for both antitetanus and
antidiphtheria among adults and adolescents who received a
single dose of ADACEL® were noninferior to rates among
those who received Td. Nearly all (>99%) subjects in the
ADACEL® and Td groups achieved seroprotective antitetanus
levels (>0.1 IU/mL), and >94% of adults and >99% of
adolescents achieved seroprotective antidiphtheria levels
(>0.1 IU/mL) in ADACEL® and Td groups (212,341).
Pertussis Antigens. The efficacy of the pertussis compo-
nents was inferred by comparing the immune responses
(GMCs) of adults and adolescents vaccinated with a single
dose of ADACEL® to those of infants vaccinated with 3 doses
of DAPTACEL® in a Swedish vaccine efficacy trial (338,342).
The efficacy of 3 doses of pediatric DAPTACEL® against
WHO-defined pertussis (>21 days of paroxysmal cough with
confirmation of B. pertussis infection by culture or serologic
testing, or an epidemiologic link to a household member with
culture-confirmed pertussis) was 85% (CI = 80%–89%)
(338,342). The GMCs of anti-PT, anti-FHA, anti-PRN, and
anti-FIM among adults and adolescents after a single dose of
ADACEL® were noninferior to those of infants after 3 doses
of DAPTACEL.® The prespecified criteria for booster
responses also were met (1,2,212,336,341).
Safety
 The safety of ADACEL® was evaluated in four clinical stud-
ies with data from 2,448 adults aged 18–64 years and 3,393
adolescents aged 11–17 years (212).
Immediate Events. No anaphylaxis was reported. Five adults
reported an immediate event within 30 minutes of vaccina-
tion (four persons [0.2%] for ADACEL® and one person
[0.2%] for Td); three of these five events were classified as
nervous system disorders (hypoesthesia/paresthesia). Eleven
adolescents reported an immediate event (six persons [0.5%]
for ADACEL® and five persons [0.6%] for Td); these events
included dizziness, syncope, or vasovagal reactions in addi-
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tion to pain and erythema at the injection site. All events
resolved without sequelae (338,341,343).
Solicited Local and Systemic Adverse Events. Rates of
erythema and swelling (Figures 3 and 4), or systemic (head-
ache, generalized body aches, and tiredness [data not pre-
sented]) adverse events reported to occur during 0–14 days
following vaccination with Td or Tdap were similar
(1,2,212,338,341). Fever >100.4°F (>38°C) was reported with
the same frequency by adults vaccinated with Td and with
Tdap (Figure 3) (212); the rate of any fever reported by ado-
lescents vaccinated with Tdap (5%) was higher than the rate
for those vaccinated with Td (3%) but met the noninferiority
criterion (Figure 4) (212,341). No case of whole-arm swell-
ing was reported (341).
Serious Adverse Events. Among adults, serious adverse
events (e.g., appendicitis) within 6 months after vaccination
were reported for 33 (2%) of 1,752 persons in the ADACEL®
group and for 11 (2%) of 573 persons in the Td group
(338,341). Two serious adverse events in ADACEL® recipi-
ents were neuropathic and were assessed by the investigators
as possibly related to vaccination. In both cases, the symp-
toms resolved completely over several days (1,212,338,
341,343). Among adolescents, serious adverse events within
6 months after vaccination were reported for 11 (1%) of 1,184
persons in the ADACEL® group and for eight (1%) of 792
persons in the Td group. All events were reported by investi-
gators to be unrelated to the study vaccine (341). No physi-
cian-diagnosed Arthus reaction (see Important Local
Reactions) or case of Guillain-Barré syndrome (see Neuro-
logic and Systemic Events) was reported (1).
Simultaneous Administration of Tdap
with Other Vaccines
Trivalent Inactivated Influenza Vaccine. The safety and
immunogenicity of ADACEL® co-administered with triva-
lent inactivated influenza vaccine ([TIV] Fluzone,® sanofi
pasteur, Swiftwater, Pennsylvania) were evaluated in nonpreg-
nant adults aged 19–64 years randomized to simultaneous
administration in different arms (n = 359), or to TIV admin-
istered first, followed by ADACEL® 4–6 weeks later (n = 361).
Rates of fever and injection site erythema and swelling were
similar following ADACEL® administered concurrently with
TIV or separately. Pain at the ADACEL® injection site
occurred more frequently after simultaneous administration
than after separate administration (67% and 61%, respectively)
(338). Immunogenicity criteria were met with the following
exceptions: the GMC of anti-PRN was lower in the simulta-
neous group than in the sequential group (338,344), and the
tetanus booster response rates were lower after simultaneous
administration than after sequential administration (79% and
83%, respectively). However, more than 98% of subjects in
both groups achieved seroprotective levels (>0.1 IU/mL) of
tetanus antitoxin (338,344).
Hepatitis B Vaccine. The safety and immunogenicity of
ADACEL® administered with hepatitis B (Hep B) vaccine
(Recombivax HB,® Merck and Co., White House Station,
New Jersey) were evaluated among nonpregnant adolescents
FIGURE 3. Frequencies of selected solicited adverse events
in adults aged 18–64 years within 15 days after a single dose
of ADACEL® tetanus, reduced diphtheria, and acellular
pertussis (Tdap) vaccine or tetanus and reduced diphtheria
toxoids (Td) vaccine — United States, 2001–2002
Source: Product label available at http://www.fda.gov/cber/index.html.
Tdap (n = 1,688–1,698)



























FIGURE 4. Frequencies of selected solicited adverse events
in adolescents aged 11–17 years within 15 days after a single
dose of ADACEL® tetanus, reduced diphtheria, and acellular
pertussis (Tdap) vaccine or tetanus and reduced diphtheria
toxoids (Td) vaccine — United States, 2001–2002
Source: Product label available at http://www.fda.gov/cber/index.html.
* Tdap did not meet the noninferiority criteria for the rate of “any” injection-
site pain compared with the Td rate (upper limit of two-sided confidence
interval on the difference in the percentage of adolescents [Tdap minus
Td] was 10.7% whereas the noninferiority criterion was <10%).
†The rate of “any” fever was higher after Tdap than after Td (p<0.05);




























Tdap (n = 1,170–1,175)
Td (n = 783–787)
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aged 11–14 years randomized to simultaneous administra-
tion (n = 206) or to ADACEL® administered first, followed
by hepatitis B vaccine 4–6 weeks later (n = 204). Rates of
solicited erythema and swelling at the ADACEL® injection
site were higher in the simultaneous group than in the
sequential group, and noninferiority was not achieved (1,338).
No interference was observed in the immune responses to any
of the vaccine antigens when ADACEL® and hepatitis B vac-
cine were administered concurrently or separately (212).
BOOSTRIX®
BOOSTRIX® contains the same tetanus toxoid, diphtheria
toxoid, and three pertussis antigens as those in INFANRIX®
(pediatric DTaP, also made by GlaxoSmithKline), but
BOOSTRIX® is formulated with reduced quantities of anti-
gens. Prelicensure trials conducted in the United States evalu-
ated the immunogenicity and safety of BOOSTRIX® among
adolescents aged 10–18 years (213,337), randomized to re-
ceive a single dose of BOOSTRIX® or a single dose of Td
(Massachusetts Public Health Biologic Laboratory, Mattapan,
Massachusetts) (Table 1) (213,334,337). Pregnant adolescents
were excluded.
Immunogenicity
Tetanus and Diphtheria Toxoids. The rates of sero-
protection and booster response for both antitetanus and
antidiphtheria among adolescents who received a single dose
of BOOSTRIX® were noninferior to those who received
Td. All adolescents had seroprotective antitetanus levels
(>0.1 IU/mL); >99% of adolescents had seroprotective
antidiphtheria levels (>0.1 IU/mL) (1,213,336).
Pertussis Antigens. The efficacy of the pertussis compo-
nents was inferred by comparing the immune responses of
adolescents vaccinated with a single dose of BOOSTRIX®
with the immune responses of infants vaccinated with 3 doses
of INFANRIX® in a German vaccine efficacy trial (213,336,
345). The efficacy of 3 doses of pediatric INFANRIX® against
WHO-defined pertussis was 89% (CI = 77%–95%)
(213,345). The GMCs of anti-PT, anti-FHA, and anti-PRN
after a single dose of BOOSTRIX® were noninferior to those
of infants after 3 doses of INFANRIX.® The prespecified cri-
teria for booster responses also were met (1,213,336,337).
Safety
A total of 3,080 adolescents aged 10–18 years received
BOOSTRIX® in the primary safety study (213). No imme-
diate events (i.e., those occurring within 30 minutes of vacci-
nation) were reported (1,213,336,337).
Solicited Local and Systemic Adverse Events. No sub-
stantial differences were observed between the BOOSTRIX®
and Td recipients in the rates of solicited local (redness, swell-
ing, and increase in arm circumference above baseline)
(Figure 5) or systemic (headache, fatigue, gastrointestinal sys-
temic events, fever >100.4°F [>38.0°C] [data not presented])
adverse events (1,213,336,337). No case of whole-arm swell-
ing was reported (1).
Serious Adverse Events. Serious adverse events within
6 months after vaccination were reported among 14 (0.4%)
of 3,005 adolescents vaccinated with BOOSTRIX® and two
(0.2%) of 1,003 adolescents vaccinated with Td. All events
were reported by the investigators to be unrelated to the study
vaccine (213,336,337,346). No physician-diagnosed Arthus
reaction or case of Guillain-Barré syndrome was reported
(1,213,337,346).
Pregnant Women Vaccinated with Tdap
Pregnant women were excluded from prelicensure trials of
Tdap. The outcome of pregnancy among six women who were
administered ADACEL® inadvertently during or within 1
month of conception was a healthy full-term infant (n = 3), a
preterm infant (n = 1), or a miscarriage (n = 2). No infant was
born with a congenital anomaly (sanofi-pasteur, unreported
data, 2007). Two pregnancies occurred in BOOSTRIX®
recipients >4 months postvaccination; one subject experienced
a spontaneous abortion within the first trimester, and the other
subject delivered a healthy infant (337).
FIGURE 5. Frequencies of selected solicited adverse events
in adolescents aged 10–18 years within 15 days after a single
dose of BOOSTRIX® tetanus, reduced diphtheria, and
acellular pertussis (Tdap) vaccine or tetanus and diphtheria
toxoids (Td) vaccine — United States, 2002–2003
Source: Product label available at http://www.fda.gov/cber/index.html.
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Regulatory Considerations for Tdap
in Pregnant Women
As with the majority of vaccines, Tdap is labeled pregnancy
category C. This designation indicates that no adequate and
well-controlled studies have been conducted with the vaccine
in pregnant women to determine the product’s safety
(347,348).
Safety Considerations for Adult
and Adolescent Use of Td or Tdap
Prelicensure studies in nonpregnant adults and adolescents
evaluated the safety of Tdap with respect to local and sys-
temic adverse events (212,213). The sample sizes were insuf-
ficient to detect rare adverse events. Enrollment criteria
excluded persons who were pregnant; had received vaccines
containing tetanus toxoid, diphtheria toxoid, or pertussis com-
ponents more recently than either the preceding 5 years for
ADACEL® (212) or the preceding 10 years for BOOSTRIX®
(213); or had certain neurologic conditions or events (336–
338,341,346). Safety data are being collected by the Vaccine
Adverse Event Reporting System (VAERS), and postlicensure
studies continue to monitor for potential adverse reactions
following widespread use of Tdap in adults and adolescents
(16,17). Registries have been established by both Tdap manu-
facturers for reporting women vaccinated with Tdap during
pregnancy.
Interval between Td and Tdap
ACIP has made several recommendations for intervals
between tetanus toxoid– and diphtheria toxoid–containing
vaccines that balance the benefits of protection against the
risks of moderate and severe local reactions. Moderate and
severe local reactions, including Arthus reaction, are associ-
ated with frequent dosing at short intervals and larger doses
of toxoid. High antitoxin levels are more likely to result when
the interval between doses is short and the number of doses
increases (349–354). High preexisting antibody titers to teta-
nus or diphtheria toxoids also are associated with increased
rates and severity of local reactions to booster doses in adults
(349,354–356).
ACIP recommends a 10-year interval for routine adminis-
tration of Td (e.g., decennial Td booster), and a 5-year inter-
val for Td when indicated for wounds management (1,2,357).
Administering Td more often than every 10 years (5 years for
certain nonclean, nonminor wounds) is not necessary to pro-
vide protection against tetanus or diphtheria; however,
administering a single dose of Tdap at an interval shorter than
5 years after Td could provide a health benefit by adding pro-
tection against pertussis (Table 2) (1,2). When Tdap is
administered to add protection against pertussis, ACIP en-
courages an interval of >5 years between the most recent Td
and the Tdap dose for adolescents because they might receive
other recommended vaccines containing tetanus or diphthe-
ria toxoids (including quadrivalent meningococcal conjugate
vaccine [MCV4] [Menactra,® sanofi pasteur, Swiftwater, Penn-
sylvania]) (2). An interval as short as 2 years is recommended
between the most recent Td and the single dose of Tdap for
health-care personnel with direct patient contact, and a
2-year interval between the most recent Td and Tdap is sug-
gested for adults in close contact with infants (1). ACIP
allows for a shorter interval between the most recent Td and
administration of Tdap in certain circumstances that might
require urgent protection (1,2).
Several studies have suggested that an interval as short as
2 years between Td and a single dose of Tdap is acceptably safe.
Three studies conducted among Canadian children and ado-
lescents evaluated the safety of Tdap (ADACEL®) at an inter-
val shorter than 5 years after Td or after pediatric DTP or DTaP
(358–360). The largest was an open-label study of 7,001 stu-
dents aged 7–19 years. Rates of local reactions were not
increased among students who had received the most recent of
5 pediatric DTP or DTaP doses, or a Td dose, >2 years before
Tdap, compared with >10 years before Tdap (358). The other
Canadian studies demonstrated similar safety when Tdap was
administered at an interval of <5 years after the previous
tetanus toxoid– and diphtheria toxoid–containing vaccine
(359,360).
Adverse reactions after Tdap (ADACEL®) administered at
an interval of <2 years from the most recent Td were evaluated
in a retrospective survey of 4,524 health-care personnel who
received Tdap at a median age of 46 years during an outbreak
of pertussis-like illness in New Hampshire in 2006
(118,215,361). For the 2,676 (59%) responses, the rates of
reactions were analyzed by interval from Td to Tdap as either
>2 years (n = 1,792) or <2 years (n = 370). The rates of pain,
redness, or swelling of moderate or severe intensity, subjective
fever, and medical visits were not higher among respondents
with an interval of <2 years between administration of Td and
that of Tdap. Three serious adverse events were reported among
adults who received Tdap at an interval >2 years after the most
recent dose of Td; causality was not assessed. The events were a
case of Guillain-Barré syndrome (not requiring hospitalization)
with onset 11 days after Tdap, a case of anaphylaxis-like reac-
tion with onset 6 days after Tdap, and a case of eosinophilic
nephritis with onset 6 days after Tdap in a health-care worker
with a history of a renal transplant (215,216).
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Important Local Reactions
Arthus Reaction
Arthus reaction (type III hypersensitivity reaction) can
occur after tetanus toxoid– or diphtheria toxoid–containing
vaccines (354,357,362–366; CDC, unpublished data, 2005).
Arthus reaction is a local vasculitis with deposition of
immune complexes and activation of complement; it occurs
in the setting of high local concentration of vaccine antigens
and high circulating antibody concentration (354,362,
363,367). The reaction is characterized by severe pain, swell-
ing, induration, edema, and hemorrhage, and occasionally by
local necrosis. Vaccine-related arthus reaction typically resolves
without sequelae. The onset of symptoms and signs is 4–12
hours after vaccination, compared with anaphylaxis (imme-
diate type I hypersensitivity reaction), which has onset within
minutes after vaccination. ACIP recommends that persons who
experience an Arthus reaction after administration of a
tetanus toxoid–containing vaccine not receive Td or other
tetanus toxoid–containing vaccine more frequently than
every 10 years, even for tetanus prophylaxis as part of wound
management (1,357).
Extensive Limb Swelling
Extensive limb swelling reactions have been reported to
VAERS following administration of Td (368,369) and are
described following dose 4 or dose 5 of pediatric DTaP
(23,208,368,370–373). Extensive limb swelling after pediat-
ric DTaP resolves without complication within 4–7 days (370),
and is not considered a precaution or contraindication for
Tdap (23).
Neurologic and Systemic Events
Pertussis Components
Concerns regarding a possible role of pertussis vaccine com-
ponents in causing neurologic reactions or exacerbating
underlying neurologic conditions in infants and children are
long-standing (29,374). In 1991, the Institute of Medicine
(IOM) concluded that evidence favored acceptance of a causal
relation between pediatric DTP vaccine and acute encephal-
opathy (365). A subsequent retrospective analysis of >2 mil-
lion children in the United States did not demonstrate that
pediatric DTP was associated with an increased risk for
encephalopathy after vaccination (375). Active surveillance
in Canada during 1993–2002 also failed to identify any acute
encephalopathy cases causally related to whole-cell or acellu-
lar pertussis vaccines among a population administered 6.5
million doses of pertussis-containing vaccines (376). Results
of one recent investigation suggested that some acute encepha-
lopathies attributed previously to pertussis-containing vaccines
could be the result of genetically determined epileptic encepha-
lopathies related to mutations in the sodium channel gene
SCN1A (377,378). A history of encephalopathy (e.g., coma
or prolonged seizures) not attributable to an identifiable cause
within 7 days of administration of a vaccine with pertussis
components remains a contraindication for Tdap (but not
Td) in adults and adolescents.
The possibility that Tdap would complicate neurologic
evaluation of chronic progressive neurologic disorders that are
stable in adults (e.g., dementia) is of limited clinical concern
and does not constitute a reason to delay administration of
Tdap (1). Unstable or evolving neurologic conditions (e.g.,
cerebrovascular events or acute encephalopathic conditions)
would be reason to delay administration of Tdap until the
condition has stabilized (1). Among adolescents who have
progressive or uncontrolled underlying neurologic disease,
concerns regarding administering Tdap must be weighed
against the morbidity from pertussis, which could be severe
(2). ACIP does not consider a history of well-controlled sei-
zures or a family history of seizures (febrile or afebrile) or other
neurologic disorder to be a contraindication or precaution to
vaccination with pertussis components (22).
Tetanus Toxoid Component
ACIP considers Guillain-Barré syndrome within 6 weeks
after receipt of a tetanus toxoid–containing vaccine to be a
precaution (see Precautions and Reasons to Defer Td or Tdap)
for administration of subsequent tetanus toxoid–containing
vaccines (23). Although IOM concluded that evidence favored
acceptance of a causal relation between tetanus toxoid–
containing vaccines and Guillain-Barré syndrome on the
basis of a single well-documented case (365,379), subsequent
analysis of data from both adult and pediatric populations
failed to demonstrate an association (380). As of January 29,
2007, eight patients with Guillain-Barré syndrome tempo-
rally associated with receipt of Tdap or of Tdap administered
on the same day with other vaccines had been reported to
VAERS. The onsets were not clustered by the interval since
vaccination or by a single pattern of vaccine exposure (361).
ACIP does not consider a history of brachial neuritis to be a
precaution or contraindication for administration of tetanus
toxoid–containing vaccines (23,381). IOM concluded that
evidence from case reports and uncontrolled studies involv-
ing tetanus toxoid–containing vaccines did favor a causal
relation between tetanus toxoid–containing vaccines and brachial
neuritis (365); however, brachial neuritis typically is self-limited
(23,381). Brachial neuritis is a compensable event through the
Vaccine Injury Compensation Program (VICP) (365).
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Economic Considerations
No study has evaluated the disease morbidity and societal
costs associated with pertussis among pregnant women or
modeled the cost benefit or cost effectiveness of a Tdap strat-
egy that includes vaccination of pregnant women. The mor-
bidity and societal cost of pertussis in adults is substantial
(1,2). A retrospective assessment of medical costs of confirmed
pertussis in 936 adults in Massachusetts during 1998–2000,
and a prospective assessment of nonmedical costs in 203 adults
during 2001–2003 (31) indicated that the mean medical and
nonmedical cost per case was $326 and $447, respectively, for
a societal cost of $773. If the cost of antimicrobials to treat
contacts and the cost of personal time were included, the
societal cost could be as high as $1,952 per adult case (31).
Cost-benefit and cost-effectiveness analyses of adult Tdap
vaccination have varied in their results (382,383). When dis-
crepancies in the models were addressed, an adult Tdap vacci-
nation program was cost-effective when incidence of pertussis
exceeded 120 cases per 100,000 population, using a bench-
mark of $50,000 per quality-adjusted life year saved (384–386).
After adjusting for the severity of the illness at high disease inci-
dence, little effect was observed on the overall cost effectiveness
of a vaccination program. Similar results were obtained when
program costs and benefits were analyzed over the lifetime of
the adult cohort for decennial booster strategies (1,387).
Implementing Tdap
Preconception Assessments
Administering a dose of Tdap during routine wellness visits
of adult and adolescent women of childbearing age, if indi-
cated, is the most effective programmatic strategy to ensure
that women are protected against pertussis in addition to teta-
nus and diphtheria and minimizes any theoretical effect of
vaccination on infant immune responses should the woman
become pregnant (see Immunity to Pertussis and Kinetics of
Pertussis Booster Vaccination in Nonpregnant Adults and
Adolescents) (1,388–392). Because Tdap contains only tox-
oids and purified bacterial components, women who receive
Tdap do not need to wait after vaccination to become preg-
nant (23). Assessments provide repeated opportunities for
documenting the history of past doses of Td (or TT) and any
serious adverse reactions to tetanus, diphtheria, and pertussis
vaccines. To access and maintain immunization records, state-
based immunization information systems (IIS) are increas-
ingly becoming available to clinicians and public health
officials. These confidential, computerized information sys-
tems, which consolidate vaccination data from multiple health-
care providers, can generate reminder and recall notifications,
assist with vaccine management and adverse events reporting,
and capture lifespan vaccination histories (393). Additional
guidance regarding administration of vaccines during routine
assessments, record keeping, vaccine storage, and related top-
ics has been published previously (23).
Prenatal Visits: Deferring Td During
Pregnancy to Substitute Tdap in the
Immediate Postpartum Period
In 2004, a total of 96% of pregnant women started prena-
tal care in the first or second trimester (394). Prenatal visits
provide additional opportunities for assessing the history of
past vaccination with Tdap, Td, or TT and any serious
adverse reactions to tetanus, diphtheria, and pertussis vaccines.
Women who have not received a previous dose of Tdap can
be advised that ACIP recommends Tdap postpartum before
discharge from the hospital or birthing center to provide per-
sonal protection and reduce the risk for transmitting pertussis
to their infants.
Health-care providers can monitor pregnant women for res-
piratory illness consistent with pertussis or for recent expo-
sure to pertussis, either to themselves or to family members,
and prescribe a macrolide antimicrobial for treatment of per-
tussis or postexposure prophylaxis, if indicated. Women and
their partners should receive counseling regarding the severity
of infant pertussis and ACIP’s recommendation for a single
dose of Tdap for adults and adolescents who anticipate con-
tact with an infant (1,2). In a 2005 national survey of obste-
tricians, 72% of respondents affirmed the belief that
obstetricians, pediatricians, adult primary care providers, and
public health providers share responsibility to promote
administration of Tdap for adults who anticipate contact with
an infant, including fathers and close relatives (395). Ideally,
health-care providers delivering prenatal care will encourage
persons likely to have contact with an infant, including child
care providers, to receive Tdap first.
When pregnant women who have not received Tdap have
indications for tetanus or diphtheria booster protection
(>10 years since the most recent Td), ACIP recommends
receipt of Td during pregnancy (Table 2). ACIP has devel-
oped criteria for safely deferring administration of Td until
delivery among women who have received past tetanus toxoid–
containing vaccinations, so the majority of these women can
substitute Tdap in the immediate postpartum period for Td
during pregnancy (see Deferring Td During Pregnancy to Sub-
stitute Tdap in the Immediate Postpartum Period). When the
history of tetanus toxoid vaccination for the women is uncer-
tain or lacking, health-care providers can determine the con-
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centration of tetanus antitoxin to ensure protective concen-
trations of tetanus antitoxin (>0.1 IU/mL by ELISA). Because
diphtheria is rare in the United States, serologic screening for
diphtheria antitoxin typically is not necessary. A woman who
anticipates travel to an area in which diphtheria is endemic can
improve protection against diphtheria by receiving a booster
dose of Td during pregnancy or a dose of Tdap postpartum.
Serologic screening to establish immunity to pertussis is not
useful.
In special situations in which a pregnant woman has
increased risk for tetanus, diphtheria, or pertussis, ACIP
acknowledges that health-care providers may choose to
administer Tdap instead of Td during pregnancy to add pro-
tection against pertussis, after discussing the theoretical ben-
efits and risks for her, her fetus, and the pregnancy outcome
with the woman before vaccination (see Considerations for
Use of Tdap in Pregnant Women in Special Situations). Data
to inform this decision are scarce. No theoretical risk for harm
to the mother or fetus exists from Tdap, and administration
of Tdap in the pregnant woman might provide a degree of
early protection to the infant against pertussis. However, a
theoretical risk for the infant is that the dose of Tdap in preg-
nancy might not result in early protection against pertussis or
could increase transplacental pertussis-specific antibodies to
levels that would have a negative effect on the infant’s response
to immunization with pediatric DTaP or with conjugate vac-
cines containing tetanus toxoid or diphtheria toxoid (e.g.,
Haemophilus influenzae type b pneumococcal conjugate vac-
cine) (222). Health-care providers who choose to vaccinate
pregnant women with Tdap are encouraged to report such
administration to the manufacturers’ pregnancy registry.
Postpartum Tdap
In 2004, a reported 99% of live births in the United States
occurred in a hospital. Of out-of-hospital live births, 27%
occurred at a free-standing birthing center and 65% at a resi-
dence (394). In these settings, attendants can implement pro-
tocols to ensure that postpartum women who have not received
Tdap previously receive it before discharge. They also can en-
courage previously unvaccinated adults and adolescents who
anticipate contact with an infant to receive Tdap. Tdap vacci-
nation of the women and potential contacts before discharge
rather than at a follow-up visit has the advantage of decreas-
ing the time when new mothers and contacts of the newborns
could acquire and transmit pertussis to the infants (1,2). Stand-
ing orders for postpartum Tdap vaccination before discharge
have successfully raised vaccination rates to more than 80%
of eligible women (396). Although obtaining a history of the
most recent Td vaccination was anticipated to be a barrier to
postpartum vaccination with Tdap, in practice it was not iden-
tified as a barrier (395,396).
Vaccination of parents and household contacts of prema-
ture infants has been advocated to ensure that such persons
receive Tdap (397). Premature and low birth weight infants
are at increased risk for severe and complicated pertussis. The
case-fatality rate for pertussis is increased compared with term
infants, and premature infants might respond less well than
term infants to initial doses of DTaP vaccine because of
comorbidities or treatments (e.g., dexamethasone) (47,53,
398–403).
Parents should be reminded of other measures to protect
infants from pertussis. To the extent feasible, parents can limit
infant exposures to persons who have respiratory illness until
they are determined to be noninfectious (99,219,321). When
pertussis exposure occurs, antimicrobial prophylaxis of exposed
contacts can be effective in preventing transmission of pertus-
sis (42,99,404,405). Ensuring that infants begin the pediatric
DTaP vaccination series at the recommended chronologic age of
6–8 weeks is critical to protection and reducing the severity of
pertussis (8,45,397,406). Administration of 2 or 3 doses of pedi-
atric DTP or DTaP can prevent hospitalization for pertussis and
its complications (5,8,407–409).
Recommendations
Recommendations for routine use of Td and Tdap among
women of childbearing age who might become pregnant have
been published previously (1,2) and have been summarized
(Table 2). Women are encouraged to receive a single dose of
Tdap either as ADACEL® (adults and adolescents aged
11–64 years) or as BOOSTRIX® (adolescents aged 11–18
years) before conception (e.g., during routine wellness visits)
if they have not already received Tdap. Recommendations for
adults and adolescents who anticipate or have household con-
tact with an infant aged <12 months also have been published
previously (1,2) and summarized (Table 2). The dose of Tdap
will provide active booster immunization against tetanus, diph-
theria, and pertussis and will replace the next dose of Td
according to routine recommendations. A single preconcep-
tion dose of Tdap will prevent pertussis, reduce morbidity
associated with pertussis, and might prevent exposing per-
sons at increased risk for pertussis and its complications,
including infants. The risk for pertussis death and severe per-
tussis is highest among infants in the first months of life and
remains elevated until an infant has received 1–2 doses of
pediatric DTaP (8,45,47).
The following sections present recommendations for use of
Td and Tdap among pregnant and postpartum women,
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including routine vaccination, contraindications, precautions,
and special situations. As with most inactivated vaccines and
toxoids, pregnancy is not a contraindication for use of Tdap.
Although the safety and immunogenicity of Tdap is expected
to be similar in pregnant and nonpregnant women, few data
on the safety of Tdap for women, fetuses, and pregnancy out-
comes are available, and no information is available on the
immunogenicity of Tdap in pregnant women. Vaccinating
pregnant women with a single dose of Tdap might provide a
degree of protection against pertussis to the infant in early life
through transplacental maternal antibody, but evidence sup-
porting this hypothesis is lacking. A concern is the unknown
effect of potential interference by maternal antibody on the
ability of the infant to mount an adequate immune response
when the infant receives pediatric DTaP or conjugate vac-
cines containing tetanus toxoid or diphtheria toxoid.
In special situations, administration of Tdap during preg-
nancy might be warranted for pregnant women who were not
vaccinated previously with Tdap. Health-care providers who
choose to administer Tdap to pregnant women should dis-
cuss with the women the potential risks and benefits of
immunization including the lack of data on Tdap adminis-
tered during pregnancy or its unknown effects on active
immunization of their infant. The following recommenda-
tions are intended to provide guidance to clinicians until ad-
ditional information is available.
1. Routine Tdap Vaccination
1-A. Recommendations for Use of Postpartum
Tdap
For women who have not received Tdap previously (includ-
ing women who are breastfeeding), Tdap is recommended as
soon as feasible in the immediate postpartum period to pro-
tect the women from pertussis and reduce the risk for expos-
ing their infants to pertussis. The postpartum Tdap should be
administered before discharge from the hospital or birthing
center. If Tdap cannot be administered at or before discharge,
the dose should be administered as soon as feasible thereafter.
Elevated levels of pertussis antibodies in the mother are likely
within 1–2 weeks after vaccination.
Although an interval of 10 years since receipt of the most
recent Td dose is recommended for the next routine Td booster,
to reduce the risk for women exposing their infants to pertus-
sis, an interval as short as 2 years between the most recent Td
and administering Tdap¶ is suggested for postpartum women.
The safety of such an interval is supported by three Canadian
studies among adolescents and by a study among nonpreg-
nant adult health-care personnel (215,358–360), an interval
shorter than 2 years may be used (see Postpartum Tdap When
<2 Years Have Elapsed Since the Most Recent Td). In this
setting, the benefit of Tdap to protect against pertussis typi-
cally outweighs the risk for local and systemic reactions after
vaccination. Routine postpartum Tdap recommendations are
supported by evidence from randomized controlled clinical
trials, nonrandomized open-label trials and a retrospective
survey, observational studies, and expert opinion (Box 2).
1-B. Dosage and Administration
The dose of Tdap or, if indicated, the dose of Td is 0.5 mL,
administered intramuscularly (IM), preferably into the
deltoid muscle.
1-C. Simultaneous Vaccination with Tdap and
Other Vaccines
If two or more vaccines are indicated, they typically should
be administered during the same visit (i.e., simultaneous vac-
cination). Each vaccine should be administered using a sepa-
rate syringe at a different anatomic site. Certain experts
recommend administering no more than two injections per
muscle, separated by at least one inch. Administering all indi-
cated vaccines during a single visit increases the likelihood
that pregnant and postpartum women will receive recom-
mended vaccinations (23).
1-D. Interchangeable Use of Tdap Vaccines
A single dose of ADACEL® may be used for adults aged
19–64 years, and a single dose of either ADACEL® or
BOOSTRIX® may be used for adolescents aged 11–18 years,
regardless of the type or manufacturer of pediatric DTP or
pediatric DTaP used for childhood vaccination.
1-E. Preventing Adverse Events
Attention to proper immunization technique, including use
of an appropriate needle length and standard routes of
administration (i.e., IM for Td and Tdap) might minimize
the risk for adverse events. Guidance for administration of
vaccines is available (23).
Syncope can occur after vaccination and might be more
common among young adults and adolescents than among
other age groups. Syncope rarely has resulted in serious injury
(23,410–412). Vaccine providers should strongly consider
observing patients for 15 minutes after they are vaccinated
(23,412). If syncope occurs, patients should be observed
until symptoms resolve.¶ An interval of 5 years since the most recent tetanus and diphtheria toxoids–
containing vaccine is encouraged for routine vaccination of adolescents who
are not pregnant (2).
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1-F. Inadvertent Administration of Pediatric
DTaP, BOOSTRIX® Tdap, or Purified Protein
Derivative (PPD)
The potential for administration errors involving tetanus
toxoid–containing vaccines (413) and other vaccines is well-
documented (414–416). Pediatric DTaP and pediatric diph-
theria toxoid and tetanus toxoid vaccine (DT) formulations
indicated for use in children aged 6 weeks–6 years should not
be administered to adults or adolescents; these vaccines can
be associated with more severe local reactions than adult for-
mulations (350,417). Packaging of adult and adolescent Tdap
vaccines, pediatric DTaP, and purified protein derivative (PPD)
might appear similar. Only one formulation of Tdap,
ADACEL,® is licensed and recommended for adults aged
19–64 years. Both formulations of Tdap (BOOSTRIX® and
ADACEL®) are licensed and recommended for adolescents
aged 11–18 years. Providers should review product labels
before administering these vaccines. If pediatric DTaP is
administered inadvertently to an adult or adolescent, or if
BOOSTRIX® is administered inadvertently to an adult aged
>19 years, the dose should be counted as the Tdap dose, and
the person should not receive an additional dose of Tdap.
Adults or adolescents who receive PPD instead of Tdap should
receive a dose of Tdap.
1-G. Record Keeping
Health-care providers who administer vaccines to adults and
adolescents are required to keep permanent vaccination records
of vaccines covered under the National Childhood Vaccine
Injury Compensation Act. ACIP has recommended that this
practice include all vaccines (23). Encouraging adults and
adolescents to maintain a personal vaccination record is
important to minimize administration of unnecessary vacci-
nations. Ideally, the personal vaccine record will document
the type of the vaccine, manufacturer, anatomic site, route,
and date of administration, and the name of the administer-
ing facility (23).
2. Contraindications and Precautions
for Use of Td and Tdap
2-A. Contraindications
The following conditions are contraindications for Td or
Tdap:
• Td and Tdap are contraindicated for persons with a his-
tory of serious allergic reaction (i.e., anaphylaxis) to any
component of the vaccine. Because of the importance of
tetanus vaccination, persons with a history of anaphy-
laxis to components included in any Td or Tdap vaccines
should be referred to an allergist to determine whether
they have a specific allergy to tetanus toxoid and whether
they can safely receive TT vaccination.
• Tdap (but not Td) is contraindicated for adults and ado-
lescents with a history of encephalopathy (e.g., coma or
prolonged seizures) not attributable to an identifiable cause
within 7 days of administration of a vaccine with pertus-
sis components. This contraindication is for the pertussis
components, and these persons should receive Td instead
of Tdap.
2-B. Precautions and Reasons to Defer
Td or Tdap
A precaution is a condition in a vaccine recipient that might
increase the risk for a serious adverse reaction (23). In the
following situations, vaccine providers should evaluate the risks
and benefits of administering Td or Tdap:
• Guillain-Barré syndrome with onset <6 weeks after previ-
ous dose of a tetanus toxoid–containing vaccine;
• moderate or severe acute illness with or without fever until
the acute illness resolves;
• history of an Arthus reaction (see Important Local
Reactions) after a previous dose of a tetanus toxoid–
containing and/or diphtheria toxoid–containing vaccine,
including MCV4. The vaccine provider should review the
patient’s medical history to verify the diagnosis of Arthus
reaction and consult with an allergist or immunologist. If
an Arthus reaction was likely, vaccine providers should
consider deferring Td or Tdap vaccination until at least
BOX 2. Summary of evidence for routine adult tetanus toxoid,
reduced diphtheria toxoid, and acellular pertussis (Tdap)
vaccination
• Efficacy against tetanus, diphtheria, and pertussis is sup-
ported by immunogenicity results from randomized,
controlled clinical trials among nonpregnant adults and
adolescents.
• Safety is supported by the results of randomized, con-
trolled clinical trials among nonpregnant adults and
adolescents; limited data are available from a retrospec-
tive survey of a small group of vaccinated pregnant
women.
• The safety of an interval of approximately 2 years
between adult tetanus and reduced diphtheria toxoids
vaccine (Td) and Tdap is supported by three  non-
randomized, open-label clinical trials among children
and nonpregnant adolescents and by preliminary results
from a retrospective survey of vaccinated adult health-
care personnel.
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10 years have elapsed since the last tetanus toxoid– or
diphtheria toxoid–containing vaccine was received. If the
Arthus reaction was associated with a vaccine that con-
tained diphtheria toxoid without tetanus toxoid (e.g.,
MCV4), deferring Td or Tdap might leave the adult or
adolescent woman and her neonate unprotected against
tetanus. In this situation, if the last tetanus toxoid–
containing vaccine was administered >10 years previously,
vaccine providers may obtain a serum tetanus antitoxin level
to evaluate the need for tetanus vaccination (tetanus anti-
toxin levels >0.1 IU/mL by ELISA are considered protec-
tive) or administer TT; and
• Tdap (but not Td) for adults aged 19–64 years with
unstable neurologic conditions (e.g., cerebrovascular
events or acute encephalopathic conditions) (1) and ado-
lescents aged 11–18 years with any progressive neurologic
disorder including progressive encephalopathy, or uncon-
trolled epilepsy (until the condition has stabilized) (2) (see
Neurologic and Systemic Events).
2-C. Conditions Under Which Td or Tdap May
Be Administered If Otherwise Indicated
The following conditions are not contraindications or pre-
cautions for Td or Tdap:
• stable neurologic disorder, including well-controlled sei-
zures, a history of a seizure disorder that has resolved, or
cerebral palsy;
• brachial neuritis after a previous dose of tetanus toxoid–
or diphtheria toxoid– containing vaccine;
• a history of an extensive limb swelling reaction that was
not an Arthus hypersensitivity reaction after pediatric DTP
or DTaP or after Td;
• immunosuppression, including persons with human
immunodeficiency virus (HIV) (the immunogenicity of
Tdap in persons with immunosuppression has not been
studied and could be suboptimal);
• breastfeeding;
• intercurrent minor illness; and
• use of antimicrobials.
Latex allergies other than anaphylactic allergies (e.g., a his-
tory of contact allergy to latex gloves) are not a contraindica-
tion or precaution to Tdap (417). The tip and rubber plunger
of the BOOSTRIX® needleless syringe contain latex. The
BOOSTRIX® single dose vial and ADACEL® preparations
contain no latex. Certain Td products contain latex. The pack-
age inserts should be consulted for details (Table 1).
3. Special Situations
3-A. Deferring Td during Pregnancy
to Substitute Tdap in the Immediate
Postpartum Period
Tetanus and diphtheria booster vaccination is recommended
for pregnant women if >10 years have elapsed since the previ-
ous Td vaccination (1,2). To add protection against pertussis,
health-care providers may defer the Td vaccination during
pregnancy to substitute Tdap as soon as feasible postpartum
if the woman is likely to have sufficient tetanus and diphthe-
ria protection until delivery.
Sufficient tetanus protection is likely if:
• a pregnant woman aged <31 years has received a com-
plete childhood series of immunization (4–5 doses of
pediatric DTP, DTaP, and DT) and >1 Td booster dose
during adolescence or as an adult (a primary series con-
sisting of 3 doses of Td (or TT) administered during ado-
lescence or as an adult substitutes for the childhood series
of immunization),**
• a pregnant woman aged >31 years has received a com-
plete childhood series of immunization (4–5 doses of
pediatric DTP, DTaP, and/or DT) and >2 Td booster
doses,
• a primary series consisting of 3 doses of Td (or TT) was
administered during adolescence or as an adult substitute
for the childhood series of immunization,** or
• a pregnant woman has a protective level of serum tetanus
antitoxin (>0.1 IU/mL by ELISA).
A woman should receive Td during pregnancy if she
• does not have sufficient tetanus immunity to protect
against maternal and neonatal tetanus, or
• requires urgent booster protection against diphtheria (e.g.,
for travel to an area in which diphtheria is endemic††).
Alternatively, health-care providers may choose to adminis-
ter Tdap instead of Td during pregnancy (see Considerations
for Use of Tdap in Pregnant Women in Special Situations).
3-B. Postpartum Tdap When <2 Years Have
Elapsed Since the Most Recent Td
Certain postpartum women (e.g., those who have received
Td or TT within 2 years of the immediate postpartum period)
might benefit from Tdap for pertussis protection. Few sub-
jects have been evaluated to determine the risk for adverse
local and systemic reactions after Tdap at intervals <2 years
** Women who have had a 3-dose series as TT instead of Td will likely have
protection against tetanus but might not be protected against diphtheria.
A protective titer of diphtheria antitoxin is >0.1 IU/mL by ELISA.
†† A list of areas in which diphtheria is endemic is available at www.cdc.gov/
travel/diseases/dtp.htm.
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since the most recent Td (or other tetanus toxoid– or diph-
theria toxoid–containing vaccine) (215). After obtaining a
history to exclude women with moderate or severe adverse
reactions following previous doses, health-care providers may
choose to administer Tdap in postpartum women who
received tetanus toxoid– or diphtheria toxoid–containing
vaccine§§ <2 years previously (see Precautions and Reasons to
Defer Td and Tdap).
Health-care providers should encourage vaccination of
household and child care provider contacts of infants aged
<12 months for protection against pertussis, according to cur-
rent recommendations (Table 2) (1,2). Women should be
advised of the symptoms of pertussis and the effectiveness of
early antimicrobial prophylaxis for themselves, their infant,
and members of their household, if pertussis is suspected (127).
3-C. History of Pertussis
Postpartum women who have a history of pertussis should
receive Tdap according to the routine recommendation (see
Recommendations for Use of Postpartum Tdap). This prac-
tice is preferred because the duration of protection induced
by pertussis is unknown (waning might begin as early as 5–10
years after infection) (4), and a diagnosis of pertussis often is
not reliably confirmed. Administering pertussis vaccine to
persons with a history of pertussis presents no theoretical safety
concern.
3-D. Considerations for Use of Tdap
in Pregnant Women in Special Situations
ACIP recommends administration of Td for booster pro-
tection against tetanus and diphtheria in pregnant women.
However, health-care providers may choose to administer Tdap
instead of Td during pregnancy to add protection against per-
tussis in special situations. In these situations, the pregnant
woman should be informed of the lack of data confirming the
safety and immunogenicity of Tdap in pregnant women, the
unknown potential for early protection of the infant against
pertussis by transplacental maternal antibodies, and the pos-
sible adverse effect of maternal antibodies on the ability of the
infant to mount an adequate immune response to antigens in
pediatric DTaP or conjugate vaccines containing tetanus tox-
oid or diphtheria toxoid.
Special situations in which Tdap might be used might
include instances when
• a pregnant woman has insufficient tetanus or diphtheria
protection until delivery, or
• a pregnant woman is at increased risk for pertussis.
Persons at increased risk for pertussis might include adoles-
cents aged 11–18 years, health-care personnel, and women
employed in institutions in which a pertussis outbreak is
occurring or living in a community in which a pertussis out-
break is occurring.
Adverse pregnancy outcomes are most common in the first
trimester (418). To minimize the perception of an association
of vaccine with an adverse outcome, vaccinating with tetanus
toxoid–containing vaccines during the second or third trimes-
ter is preferred.
Because information on the use of Tdap in pregnant women
is lacking, both manufacturers of Tdap have established a preg-
nancy registry. Health-care providers are encouraged to
report vaccination of pregnant women with Tdap, regardless
of trimester, to the appropriate manufacturer’s registry. For
ADACEL,® vaccination should be reported to sanofi pasteur,
telephone 1-800-822-2463 (1-800-VACCINE), and for
BOOSTRIX,® vaccination should be reported to
GlaxoSmithKline Biologicals, telephone 1-888-825-5249.
3-E. Tetanus Prophylaxis for Wound
Management
ACIP has recommended administering tetanus toxoid–
containing vaccine and tetanus immune globulin (TIG) as
part of standard wound management to prevent tetanus
(Table 11) (357). A Td booster might be recommended for
wound management in pregnant women if 5 years or more
have elapsed since the previous Td (1,2). Health-care provid-
ers may choose to substitute Tdap for Td during pregnancy
in these women (see Considerations for Use of Tdap in Preg-
nant Women in Special Situations). For pregnant women vac-
cinated previously with Tdap, Td should be used if a tetanus
toxoid–containing vaccine is indicated for wound care. Preg-
nant women who have completed the 3-dose primary tetanus
vaccination series and have received a tetanus toxoid–contain-
ing vaccine within the preceding 5 years are protected against
tetanus and do not require a tetanus toxoid–containing vac-
cine as part of wound management.
To avoid unnecessary vaccination, health-care providers
should attempt to determine whether the woman has com-
pleted the 3-dose primary tetanus vaccination series. Pregnant
women with unknown or uncertain previous tetanus vaccina-
tion histories should be considered to have had no prior teta-
nus toxoid–containing vaccine and they should complete a
3-dose primary series of immunization to prevent maternal
and neonatal tetanus (see Pregnant Women with Unknown
§§ Tetanus toxoid– and/or diphtheria toxoid–containing vaccines include
pediatric DTP, DTaP, DT, other pediatric combination vaccines including
any of these components (e.g., pediatric DTaP–inactivated poliovirus
vaccine–Hep B and pediatric DTaP–Haemophilus influenzae type b), and
adult and adolescent Td, Tdap, and TT). MCV4 contains diphtheria toxoid
but not tetanus toxoid (2).
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or Incomplete Tetanus Vaccination). Pregnant women who
have not completed the primary series might require tetanus
toxoid and passive vaccination with TIG at the time of wound
management (Table 11). When both TIG and a tetanus tox-
oid–containing vaccine are indicated, each product should be
administered using a separate syringe at different anatomic
sites. Pregnant women with a history of Arthus reaction after
a previous dose of a tetanus toxoid–containing vaccine should
not receive a tetanus toxoid–containing vaccine until 10 years
or more after the most recent dose, even if they have a wound
that is neither clean nor minor. If the Arthus reaction was
associated with a vaccine that contained diphtheria toxoid
without tetanus toxoid (e.g., MCV4), deferring Td or Tdap
might leave the pregnant women inadequately protected
against tetanus, and TT should be administered (see Precau-
tions and Reasons to Defer Td or Tdap). In all circumstances,
the decision to administer TIG is based on the primary vacci-
nation history for tetanus (Table 11).
3-F. Pregnant Women with Unknown
or Incomplete Tetanus Vaccination
Pregnant women who never have been vaccinated against
tetanus (i.e., have received no dose of pediatric DTP, DTaP,
or DT or of adult Td or TT) should receive a series of three
vaccinations containing tetanus and diphtheria toxoids start-
ing during pregnancy to ensure protection against maternal
and neonatal tetanus. A primary series consists of a first dose
administered as soon as feasible, a second dose at least 4 weeks
later, and a third dose 6 calendar months after the second
dose. If feasible, pregnant women who have received fewer
than 3 doses of tetanus toxoid–containing vaccine should com-
plete the 3-dose primary series during pregnancy. Td is pre-
ferred for the doses during pregnancy. Health-care providers
may choose to substitute a single dose of Tdap for 1 dose of
Td during pregnancy and complete the series with Td. In such
cases, the women should be informed of the lack of data on
safety, immunogenicity, and pregnancy outcomes for preg-
nant women who receive Tdap (see Considerations for Use of
Tdap in Pregnant Women in Special Situations).
Reporting Adverse Events after
Vaccination
As with any newly licensed vaccine, surveillance for rare
adverse events associated with administration of Tdap is
important for assessing its safety in large-scale use. The
National Childhood Vaccine Injury Act of 1986 requires
health-care providers to report specific adverse events that fol-
low tetanus, diphtheria, or pertussis vaccination. A table of
reportable events following vaccination is available from
VAERS at http://vaers.hhs.gov/reportable.htm. All clinically
significant adverse events should be reported to VAERS even
if causal relation to vaccination is not certain. VAERS report-
ing forms and information are available electronically at
http://www.vaers.hhs.gov or by telephone, 1-800-822-7967.
To promote better timeliness and quality of safety data, provid-
ers are encouraged to report electronically by using web-based
reporting (https://secure.vaers.orgVaersDataEntryintro.htm).
Vaccine Injury Compensation Program
VICP is a system established by the National Childhood
Vaccine Injury Act of 1986 that enables compensation to be
paid on behalf of a person thought to have been injured or
died as a result of receiving a vaccine covered by the program.
Anyone receiving a covered vaccine, regardless of age, can file
TABLE 11. Guide to tetanus prophylaxis in routine wound management among pregnant women aged 11–64 years
No. doses of adsorbed,      Clean, minor wound        All other wounds*
tetanus toxoid–containing vaccine   Td† TIG     Td TIG
Unknown number or <3 doses Yes No Yes Yes
>3 doses
>10 yrs since most recent dose Yes No Yes No
5–9 yrs since most recent dose No No Yes No
<5 yrs since most recent dose No No No No
* For example, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; avulsions; and wounds resulting from missiles, crushing, burns, and
frostbite.
†Adult tetanus and diphtheria toxoids vaccine (Td) is preferred to tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) for
pregnant women who have never received Tdap. Tdap is preferred to Td for nonpregnant adults and adolescents who have never received Tdap. In
special situations, use of Tdap during pregnancy might be warranted. Health-care providers who choose to administer Tdap during pregnancy should
discuss with the women the lack of evidence of safety and effectiveness for the mother, fetus, pregnancy outcome, and the lack of evidence of the
effectiveness of transplacental maternal antibodies to provide early pertussis protection to the infant. In addition, no study has examined the effectiveness
of transplacental pertussis antibodies induced by Tdap on the adequacy of the infant immune response to pediatric DTaP and conjugate vaccines containing
tetanus toxoid or diphtheria toxoid. Because adverse outcomes of pregnancy are most common in the first trimester, vaccinating pregnant women with Tdap
during the second or third trimester is preferred to minimize the perception of an association of Tdap with an adverse outcome, unless vaccine is needed
urgently. Td is preferred to tetanus toxoid vaccine (TT) for adults who received Tdap previously or who require tetanus protection when Tdap is not available.
If TT and tetanus immune globulin (TIG) are both used, tetanus toxoid adsorbed rather than tetanus toxoid (fluid vaccine) should be administered.
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a petition under VICP. The program is intended as an alter-
native to civil litigation under the traditional tort system
because negligence need not be proven.
The Act establishes 1) a vaccine injury table that lists the
vaccines covered by the program; 2) the injuries, disabilities,
and conditions (including death) for which compensation
might be paid without proof of causation; and 3) the period
after vaccination during which the first symptom or substan-
tial aggravation of the injury must appear. Persons might be
compensated for an injury listed in the table or one that can
be demonstrated to result from administration of a listed vac-
cine. All tetanus toxoid–containing vaccines and vaccines with
pertussis components (e.g., Tdap, Td, and pediatric DTaP)
are covered under the Act. Additional information regarding
the program is available at http://www.hrsa.gov/vaccine
compensation or by telephone, 1-800-338-2382.
Areas for Future Research
Interest in vaccinating pregnant women to prevent infant
pertussis declined in the late 1940s when whole-cell vaccine
trials demonstrated pertussis-specific antibodies in as many as
75% of infants vaccinated starting at birth or in the first few
months of life (38,186,188,218,237) and infant and child-
hood vaccination was adopted as the primary national strat-
egy for protection against childhood diseases (419,420). Aside
from initiatives to eliminate neonatal tetanus and more re-
cently to prevent influenza during pregnancy, limited atten-
tion has been focused on vaccinating pregnant women as a
strategy to prevent disease in the women and their infants
during the first few months of life (290,421–430). A major
barrier to conducting vaccine trials in pregnant women is the
potential liability from expected adverse pregnancy outcomes
that might be related temporally to vaccination (388,431,432).
However, the high morbidity and mortality of certain infec-
tions that affect pregnant women and neonates warrant re-
newed consideration of the strategy of vaccinating pregnant
women.
Ensuring the safety of vaccination for mother and fetus and
for pregnancy outcomes is a public health priority. In addi-
tion, important considerations include understanding whether
a degree of protection might be achieved for the mother and
for her newborn by vaccinating during pregnancy, whether
maternal vaccination would be required with each pregnancy
to achieve these benefits (if any), and whether change in the
levels of transplacental maternal antibody might affect infant
responses to routine vaccination (159,222,224,228). Because
few vaccines are currently recommended for pregnant women
(e.g., Td and influenza), the effects of the transplacental
maternal antibodies on the subsequent infant responses to rou-
tine vaccination with the same antigens are not known for
most vaccines. Change in the levels of transplacental antibody
can affect infant susceptibility to disease at a population level.
For example, a decrease over time in the level of transplacen-
tal maternal antibody from women who were immunized with
measles vaccine during childhood (rather than by measles dis-
ease) resulted in susceptibility to measles among their infants
at an earlier age, and to the decision to recommend infant
measles vaccination at age 12 months rather than age 15–18
months in the United States (228,433,434).
Major gaps exist in the knowledge of how best to prevent
pertussis in early infancy. These include 1) the safety of per-
tussis vaccines for pregnant women, their fetuses, and preg-
nancy outcomes; 2) the immunogenicity of acellular pertussis
vaccines in pregnant women and transplacental maternal an-
tibodies with respect to the timing of immunization during
pregnancy; 3) the degree and duration of protection against
pertussis in early infancy through transplacental maternal an-
tibodies; and 4) the effects of transplacental maternal anti-
bodies (induced by pertussis, DTP, DTaP, and/or Tdap) on
the infant responses to active immunization with pediatric
DTaP and conjugate vaccines containing tetanus toxoid or
diphtheria toxoid (159,222,234,235,435). To understand the
range of options for protecting women and infants from per-
tussis, studies are needed to determine the safety and any ben-
efits of accelerated infant pertussis vaccination schedules or
dosing (e.g., pertussis vaccination starting at birth or employ-
ing acellular vaccines that do not contain diphtheria toxoid
and tetanus toxoid) (221,436,437). Alternative infant vacci-
nation strategies examined independently or in conjunction
with vaccinating pregnant women will determine the most
effective and practical approaches to reduce the morbidity and
mortality of pertussis.
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Appendix A
Summary of ACIP Recommendations for Prevention
of Pertussis, Tetanus and Diphtheria Among Pregnant
and Postpartum Women and Their Infants
Use of Td or Tdap in Women Who Have
Not Received Tdap Previously
• Routine postpartum Tdap. Pregnant women (includ-
ing women who are breastfeeding) who have not received
a dose of Tdap previously should receive Tdap after
delivery and before discharge from the hospital or birthing
center if 2 years or more have elapsed since the most
recent administration of Td; shorter intervals may be used
(see Special Situations). If Tdap cannot be administered
before discharge, it should be administered as soon as fea-
sible thereafter. The dose of Tdap substitutes for the next
decennial dose of Td.
• Simultaneous administration. Tdap should be admin-
istered with other vaccines that are indicated. Each vac-
cine should be administered using a separate syringe at a
different anatomic site.
Contraindications to Administration of
Td and Tdap
The following conditions are contraindications to adminis-
tration of Td and Tdap:
• a history of serious allergic reaction (i.e., anaphylaxis) to
any component of the vaccine, or
• for Tdap (but not Td), a history of encephalopathy (e.g.,
coma or prolonged seizures) not attributable to an identi-
fiable cause within 7 days of administration of a vaccine
with pertussis components.
Precautions and Reasons to Defer
Administration of Td or Tdap
The following conditions are reasons to defer administra-
tion of Td or Tdap:
• Guillain-Barré syndrome with onset 6 weeks or less after
a previous dose of tetanus toxoid–containing vaccine;
• moderate or severe acute illness;
• a history of an Arthus reaction to tetanus toxoid– and/or
diphtheria toxoid–containing vaccine less than 10 years
previously;
• for adults, unstable neurologic conditions (e.g., cerebrovas-
cular events or acute encephalopathic conditions); or
• for adolescents, any progressive neurologic disorder,
including progressive encephalopathy or uncontrolled epi-
lepsy (until the condition has stabilized).
Special Situations
Deferring Td During Pregnancy to Substitute
Tdap in the Immediate Postpartum Period
ACIP recommends administration of Td for booster vacci-
nation during pregnancy if 10 years or more have elapsed since
a previous Td booster. To add protection against pertussis,
health-care providers may defer the Td vaccination during
pregnancy and substitute Tdap as soon as feasible after deliv-
ery if the woman is likely to have sufficient tetanus and diph-
theria protection until delivery. Sufficient tetanus protection
is likely if:
• a pregnant woman aged <31 years has received a com-
plete childhood series of immunization (4–5 doses of pe-
diatric DTP, DTaP, and/or DT) and >1 Td booster dose
during adolescence or as an adult (a primary series con-
sisting of 3 doses of Td (or TT) administered during ado-
lescence or as an adult substitutes for the childhood series
of immunization),*
• a pregnant woman aged >31 years has received a com-
plete childhood series of immunization (4–5 doses of pe-
diatric DTP, DTaP, and/or DT) and >2 Td booster doses,
• a primary series consisting of 3 doses of Td (or TT) was
administered during adolescence or as an adult substitute
for the childhood series of immunization,* or
• a pregnant woman has a protective level of serum tetanus
antitoxin (>0.1 IU/mL by ELISA).
A woman should receive Td during pregnancy if she
• does not have sufficient tetanus immunity to protect
against maternal and neonatal tetanus, or
• requires booster protection against diphtheria (e.g., for
travel to an area in which diphtheria is endemic†).
* Women who have had a 3-dose series as TT instead of Td will likely have
protection against tetanus but might not be protected against diphtheria. A
protective titer of diphtheria antitoxin is >0.1 IU/mL by ELISA.
† A list of areas in which diphtheria is endemic is available at www.cdc.gov/
travel/diseases/dtp.htm.
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Alternatively, health-care providers may choose to adminis-
ter Tdap instead of Td during pregnancy (see Considerations
for Use of Tdap in Pregnant Women in Special Situations).
Postpartum Tdap When <2 Years Have
Elapsed Since the Most Recent Dose of Td
Health-care providers should obtain a history of adverse
reaction after previous doses of vaccines containing tetanus
and diphtheria toxoids. Limited information is available con-
cerning the risk for local and systemic reactions after Tdap at
intervals of <2 years. Providers may choose to administer Tdap
to these women postpartum for protection against pertussis
after excluding a history of moderate to severe adverse reac-
tions following previous tetanus and diphtheria-toxoids–
containing vaccines.
Health-care providers should encourage vaccination of
household and child care provider contacts of infants aged
<12 months. Women should be advised of the symptoms of
pertussis and the effectiveness of early antimicrobial prophy-
laxis, if pertussis is suspected.
Considerations for Use of Tdap in Pregnant
Women in Special Situations
ACIP recommends that Td be administered when booster
protection is indicated during pregnancy. Health-care providers
may choose to administer Tdap instead of Td during preg-
nancy to add protection against pertussis in situations when
Td cannot be delayed until delivery or when the risk for per-
tussis is increased. In such cases, the women should be in-
formed of the lack of data on safety, immunogenicity, and
pregnancy outcomes for pregnant women who receive Tdap.
Whether administration of Tdap to pregnant women results
in protection of the infant against pertussis through transpla-
cental maternal antibodies is unknown. Maternal antibodies
might interfere with the infant’s immune response to infant
doses of DTaP or conjugate vaccines containing tetanus tox-
oid or diphtheria toxoid.
If Tdap is administered, the second or third trimester is
preferred unless protection is needed urgently. Providers are
encouraged to report Tdap administrations regardless of
trimester to the appropriate manufacturers’ pregnancy
registry: for ADACEL,® to sanofi pasteur, telephone
1-800-822-2463 (1-800-VACCINE) and for BOOSTRIX,®
to GlaxoSmithKline Biologicals, telephone 1-888-825-5249.
Tetanus Prophylaxis for Wound Management
ACIP recommends administration of a Td booster for
wound management in pregnant women in certain situations
if >5 years have elapsed since the previous Td. Health-care
providers may choose to administer Tdap instead of Td dur-
ing pregnancy to add protection against pertussis in these situ-
ations. In such cases, the women should be informed of the
lack of data on safety, immunogenicity, and pregnancy out-
comes for pregnant women who receive Tdap (see Consider-
ations for Use of Tdap in Pregnant Women in Special
Situations).
Pregnant Women with Unknown or
Incomplete Vaccination
Pregnant women who have not received 3 doses of a vac-
cine containing tetanus and diphtheria toxoids should com-
plete a series of three vaccinations, including 2 doses of Td
during pregnancy, to ensure protection against maternal and
neonatal tetanus. The preferred schedule in pregnant women
is 2 doses of Td separated by 4 weeks and 1 dose of Tdap
administered 6 months after the second dose (postpartum).
Health-care providers may choose to substitute a single dose
of Tdap for a dose of Td during pregnancy. In such cases, the
women should be informed of the lack of data on safety, im-
munogenicity, and pregnancy outcomes for pregnant women
who receive Tdap (see Considerations for Use of Tdap in Preg-
nant Women in Special Situations).
Reporting Adverse Events after Vaccination
All clinically significant adverse events should be reported
to VAERS even if a causal relation to vaccination is uncertain.
VAERS reporting forms and information are available at
http://www.vaers.hhs.gov or by telephone, 1-800-822-7967.
Providers are encouraged to report adverse events electroni-
cally at https://secure.vaers.org/VaersDataEntryintro.htm.
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Appendix B
Abbreviations Used in This Report
IIS Immunization Information Systems
IPV Inactivated poliovirus vaccine
IM intramuscularly
IOM Institute of Medicine
IU international units
Lf limit of flocculation unit
MCV4 Quadrivalent meningococcal conjugate vaccine
mL Milliliter
NNDSS National Notifiable Disease surveillance System
PCR polymerase chain reaction
PRN pertactin, 69kDa protein
PPD tuberculin purified protein derivative
PT pertussis toxin, lymphocytosis promoting
factor
Tdap adult tetanus toxoid, reduced diphtheria toxoid
and acellular pertussis vaccine
Td adult tetanus and reduced diphtheria toxoids
vaccine
TIG tetanus immune globulin
TIV trivalent inactivated influenza vaccine
TT tetanus toxoid vaccine
VAERS Vaccine Adverse Event Reporting System
VICP Vaccine Injury Compensation Program
WHO World Health Organization
ACIP Advisory Committee on Immunization
Practices
Anti-FHA Antibody directed against filamentous
hemagglutinin
Anti-FIM Antibody directed against fimbrial proteins
Anti-PRN Antibody directed against pertactin
Anti-PT Antibody directed against pertussis toxin
CI confidence interval
CSTE Council of State and Territorial
Epidemiologists
DFA direct fluorescent antibody
DT pediatric diphtheria and tetanus toxoids
vaccine
DTaP pediatric diphtheria and tetanus toxoids
and acellular pertussis vaccine
DTP pediatric diphtheria and tetanus toxoids
and whole-cell pertussis vaccine
ELISA Enzyme-linked immunoabsorbant assay
FDA Food and Drug Administration
FHA filamentous hemagglutinin
FIM Fimbriae
GMC geometric mean antibody concentration
Hep B Hepatitis B vaccine
Hib Haemophilus influenzae type b
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